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FIELD OF THE INVENTION 
The present invention relates generally to a hydrogels com-
prising covalent and noncovalent crosslinks. 
BACKGROUND OF THE INVENTION 
Over the past two decades the development of novel drug 
delivery systems has had a tremendous impact on medicine, 
allowing for the improvement of many existing therapeutics 
as well as enabling the use of entirely new therapies. Along 
with these improvements there has been a move to miniatur-
ize drug delivery devices from the macroscale (>I mm) to the 
macroscale (100-0.01 µm) or nanoscale (100-1 mu). One goal 
of developing these devices is to provide for the in situ deliv-
ery of therapeutic compounds. Therefore, a main area of 
investigation concerns the development of integrated systems 
that combine the nanotechnology with therapeutic molecules, 
for example, drugs, or biopolymers. 
However, these new technologies must overcome several 
crucial and significant obstacles. For example, new 
approaches are required that allow for the delivery of 
insoluble, or unstable compounds. In addition, these 
approaches must address situations in which the therapeutic 
molecule is rare, or difficult to purify. Furthermore, these 
approaches must allow for localized delivery of potent com-
pounds, and provide for improved compliance by reducing 
the chances of missing or erring in a dose. Lastly, these 
devices cannot be so small that they are unable to deliver an 
adequate dose. 
In addition, to date a number of peptides and proteins have 
been explored for pharmaceutical applications by virtue of 
their high biological activity and specificity. Despite potential 
advantages offered by these drugs, their application may suf-
fer because of the high molecular weight, hydrophilicity and 
low stability, which are reflected in poor biopharmaceutical 
properties. In particular, peptides and proteins undergo rapid 
clearance from the body, which takes place by a combination 
of events including proteolysis, renal ultrafiltration, and liver 
clearance. 
The development of functionalized polymers that can elicit 
specific biological responses, as well as the development of 
2 
methods to fabricate these biologically functionalized poly-
mers, is a viable approach for such therapeutic applications, 
in which delivery of molecules such as those above is desir-
able. For example, the generation of fibrous matrices with 
5 biological properties and fiber diameters commensurate with 
those of the natural extracellular matrix (ECM) may permit 
the development of novel materials for use not only in drug 
delivery, but also in wound healing or tissue engineering. 
Synthetic polymers, which can be designed to mimic some 
io functions of biopolymers, have been actively developed as 
drug delivery matrices due to their industrial and scientific 
value. They represent a primary polymeric vehicle for the 
delivery of drugs and biomolecules, owing to their simple 
synthesis, ease of processing, and range of physical proper- 
15 ties. Polymers such as proteins, polysaccharides, and nucleic 
acids, which are present as basic components in living organic 
systems, have also found some use in drug delivery and bio-
materials applications, particularly for biopolymers such as 
collagen and alginate, which have desired mechanical and 
20 biological properties. There remains a significant need, how-
ever, for the facile production of polymeric materials in which 
mechanical and biological properties can be easily modified 
in a modular fashion, without relying solely on the naturally 
occurring mechanical properties of the biological polymers 
25 or the lack of biological activity of synthetic polymers. 
One approach to the use of polymers in drug delivery 
applications involves the response of a polymer system to 
certain stimuli, which is a common process for biopolymers 
in living organisms. Stimuli responsive polymers can provide 
3o avariety of applications for the biomedical fields. The interest 
in these polymers has increased dramatically due to their 
promising potential. Among others, temperature and pH 
responsive mechanisms have been investigated as they are 
relatively convenient and effective stimuli in a variety of 
35 applications. Such stimuli-responsive polymers have been 
utilized in various forms, including cross-linked (penna-
nently) hydrogels, reversible hydrogels, micelles, modified 
interfaces, and conjugated solutions, among others. 
There has also been developing interest by the scientific 
40 community in applying methods from engineering and the 
life sciences to create artificial constructs directed to tissue 
regeneration, and thus, providing a minimally invasive and 
less painful way to treat patients. The basic protocol for the 
tissue engineering approach includes isolating specific cells 
45 by obtaining them through a biopsy from a patient, growing 
them on a three-dimensional scaffold under controlled cul-
ture conditions, delivering the construct to the desired loca-
tion in the patient's body and directing new tissue formation 
into the scaffold that will be degraded over time. Successful 
5o regeneration of damaged organs or tissues based on tissue 
engineering requires several critical elements, not the least of 
which includes biomaterial scaffolds that serve as a mechani-
cal support for cell growth. 
Materials are important in most tissue engineering strate- 
55 gies as they can serve as a substrate on which cell populations 
can attach and migrate, be implanted with a combination of 
specific cell types as a cell delivery vehicle, and be utilized as 
a drug carrier to activate specific cellular function in the 
localized region. 
60 	 The modification ofbiomaterials with bioactivemolecules 
has been found useful in designing biomimetic scaffolds that 
can provide biological cues to elicit specific cellular 
responses and direct new tissue formation. The surface and 
bulk modification of materials with peptide sequences or with 
65 bioactive proteins or other biomolecules, for example, can 
allow for the modulation of cellular functions such as adhe-
sion, proliferation and migration through alterations of pep- 
US 8,367,639 B2 
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4 
tide concentration or its spatial distribution. A variety of cell 
	
Of such bioactive molecules, glycosaminoglycans have 
binding peptides have been introduced into three dimensional 
	
been demonstrated to mediate a wide range of biological 
networks through physical, chemical, photochemical, and 	 activities such as cell adhesion, cell mobility, cell prolifera- 
ionic crosslinking. The molecules have been attached to a 	 tion and tissue morphogenesis via binding to various cell 
variety of polymeric substrates for varying applications, but a 5 regulatory proteins such as the chemokines, growth factors, 
need still remains for methods for simple modification of 	 enzymes, enzyme inhibitors, and extracellular matrix pro- 
materials with multiple bioactive molecules in a manner that 	 teins. The well studied glycosaminoglycan, heparin, is a lin- 
can control their release. 	 ear, unbranched, highly sulfated polysaccharide chain, and it 
Electrospinning is an attractive approach to polymer pro- 	 is well accepted that the electrostatic interactions between the 
cessing. The control of fiber diameter, porosity, and fiber io sulfates of the glycosaminoglycan and basic residues of a 
surface morphology makes electrospun fibers useful in a 	 protein play an important role in binding. In particular, the 
range of applications including filtration, electronic, and bio- 	 spatial orientation of the basic residues is a major determinant 
medical applications. Electrospun fibers are ideal for use in 	 of heparin-binding ability, and variations in the pattern of the 
biomedical applications such as tissue engineering and drug 	 sulfation of the heterogeneous heparin therefore permit bind- 
delivery due to the three-dimensional nanometer scale matrix 15 ing between heparin and a wide range of binding partners. 
that can be quickly produced using small quantities of starting 	 Accordingly, heparin has been incorporated into covalent 
material (<50 mg) on the laboratory scale. Larger matrices 	 hydrogel delivery systems because of this ability to bind a 
can also easily be made via the scaling up of materials that 	 diverse set of proteins. In addition, we and others have dem- 
prove to have useful materials and biological properties on the 	 onstrated that the interactions between heparin and specific 
laboratory scale. Collagen, fibrinogen, chitosan, poly(lactic 20 HBPs can also mediate the assembly of noncovalently asso- 
acid), poly(L-lactide-co-p-caprolactone), and poly(D,L-lac- 	 ciated hydrogel networks (see, for example, N. Yamaguchi, 
tide-co-glycolide) are just a few of the polymers being inves- 	 K. L. Kiick, Polysaccharide poly (ethylene glycol) star 
tigated for use in electrospun drug delivery and tissue engi- 	 copolymers as scalolds for the production of bioactive hydro- 
neering constructs due to their biocompatibility. Electrospun 	 gels, Biomacromolecules 6 (4) (2005) 1921-1930; N. 
fibers mimic the size scale of fibrous proteins found in the 25 Yamaguchi et al., Rheological characterization of polysac- 
extracellular matrix (50-150 mu) and the three-dimensional 	 charide poly (ethylene glycol) star copolymer hydrogels, 
nature of the matrix allows for cells to infiltrate the matrix and 
	
Biomacromolecules 6 (4) (2005) 1931-1940; B. L. Seal, A. 
proliferate. A variety of additional polymers can also be elec- 	 Panitch, Physical polymer matrices based on affinity interac- 
trospun into matrices for drug delivery, tissue engineering, 	 tions between peptides and polysaccharides, Biomacromol- 
and other applications. For example, see Z. M. Huang, Y. Z. 30 ecules 4 (6) (2003) 1572-1582). 
Zhang, M. K. Kotaki and S. Ramakrishna, Composites Sci. 	 Because hydrogels can mimic the high water content and 
and Tech. 2003, 63, 2223-2253, (US Patent publication No. 	 mechanical properties of natural tissues, they are prime can- 
US20030137069). 	 didates as carriers of bioactive agents, in bioadhesive sys- 
Although there have been reports of the use of electrospun 	 tems, or as biorecognizable materials. Given that poly (eth- 
fibers as scaffolds for select drug delivery and biomaterials 35 ylene glycol), or PEG, is highly hydrophilic and generally 
applications, the incorporation of bioactive molecules has not 	 nonadhesive to proteins or cells, it has found widespread use 
been widely exploited. In one example, tetracycline was 	 as a drug carrier, and many PEG hydrogels have been pro- 
included in a solution of poly(lactic acid) (PLLA) and poly 	 duced from aqueous solutions containing linear or branched 
(ethylene-co-vinyl acetate) and electrospun in a fiber mem- 	 PEG macromolecules via chemical crosslinking. In addition 
brane to study the release profile of the fiber-encapsulated 40 to hydrogels formed via radical crosslinking reactions, PEG 
drug. PLLA has also been studied as a matrix to incorporate 	 hydrogels have been formed, for example, via Michael-type 
the drugs rifampin (to treat tuberculosis) and paclitaxel (anti- 	 addition reactions upon mixing with thiol-bearing com- 
cancer drug). Polymers loaded with both of these therapeutic 	 pounds or via the reaction between amino-terminated poly 
molecules could be fabricated into nanometer to micron 	 (ethylene glycol) and the herbal iridoid glycoside genipin. In 
diameter electrospun PLLA fibers and used for delivery of the 45 some cases, cell adhesive peptide domains or biodegradable 
drug. 	 sequences have been introduced into PEG hydrogels to 
While the development of functionalized polymers that can 	 endow them with more biological signaling functions, includ- 
elicit specific biological responses is of great interest in the 	 ing the capacity for growth factor delivery. Accordingly, there 
biomedical community, as well as the development of meth- 	 have been a variety of covalently crosslinked hydrogel sys- 
ods to fabricate these biologically functionalized polymers, 50 tems developed to deliver growth factors via mechanisms 
there is still a need for more facile methods to create biologi- 	 such as diffusion and chemical or enzymatic reaction. 
cally active functionalized matrices that permit immobiliza- 	 Noncovalent interactions provide an alternative method for 
tion and long-term delivery of biomolecules and other small 	 crosslinking, as introduced above, removing the need for 
functioning molecules, moieties, and/or particles. 	 toxic chemical crosslinking agents in gel preparation. In addi- 
For example, although there have been studies demonstrat-  55 tion, noncovalent crosslinking strategies may offer advan- 
ing the utility of functionalizing electrospun fibers, the func- 	 tages in maintaining protein integrity and bioactivity until 
tionalization of electrospun fibers to confer specific biologi- 	 delivery. Polymer hydrogels have been formed via specific 
cal activity would be particularly advantageous for many 	 recognition events such as reversible antibody-antigen inter- 
biomaterial applications, as such modification would permit 	 actions (see T. Miyata et al., A reversibly antigen-responsive 
the fabrication of biomaterials that are structurally relevant 6o hydrogel, Nature 399 (6738) (1999) 766-769) and coiled-coil 
and that possess properties designed to treat or address spe- 	 interactions (see for example, C. Y. Xu et al., Reversible 
cific problems. In addition, such incorporation could serve to 	 hydrogels from self-assembling genetically engineered pro- 
protect bioactive molecules, release them in relevant time- 	 tein block copolymers, Biomacromolecules 6 (3) (2005) 
frame, and incorporate multiple suchmolecules. Inparticular, 	 1739-1749; C. Wang et al., Hybrid hydrogels assembled from 
the development of simple methods to produce multifunc-  65 synthetic polymers and coiled-coil protein domains, Nature 
tional electrospun fibers would advance the development of 
	
397 (6718) (1999) 417-420; W. A. Petka, et al., Reversible 
electrospun fibers for biomedical applications. 	 hydrogels from self-assembling artificial proteins, Science 
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281 (5375) (1998) 389-392). There has been little attention 
given, however, to the interaction between peptides (particu-
larly coiled-coils) and polysaccharides in hydrogel assembly. 
Further, the fabrication of biologically active fibers through 
such functionalization strategies is a fairly new and unex-
plored area in the field of electrospinning, and electrospun 
fibers have not been investigated for their ability to incorpo-
rate growth factor binding glycosaminoglycans, such as hep-
arin, in a manner designed to control release. 
SUMMARY OF THE INVENTION 
The invention is directed to a hydrogel comprising a poly-
mer matrix comprising a noncovalent crosslink and a covalent 
crosslink, wherein the noncovalent crosslink comprises a first 
and a second PEG-LMWH conjugate and a heparin-binding 
compound, wherein the PEG molecule of each conjugate is 
covalently attached to the polymer matrix, and wherein the 
LMWH molecule of each conjugate is covalently attached to 
the PEG molecule of the same conjugate and noncovalently 
attached to the heparin-binding compound, and wherein the 
covalent crosslink comprises a first and a second PEG mol-
ecule and a LMWH molecule, wherein each PEG molecule is 
covalently attached to the polymer matrix and covalently 
attached to the LMWH molecule. 
The invention is also directed to a hydrogel comprising a 
polymer matrix comprising a noncovalent crosslink and a 
covalent crosslink, wherein the noncovalent crosslink com-
prises a first and a second PEG-LMWH conjugate and a first 
heparin-binding compound, wherein the PEG molecule of 
each conjugate is covalently attached to the polymer matrix, 
and wherein the LMWH molecule of each conjugate is 
covalently attached to the PEG molecule of the same conju-
gate and noncovalently attached to the first heparin-binding 
compound, and wherein the covalent crosslink comprises 
either (i) a third and a fourth PEG-LMWH conjugate and a 
second heparin-binding compound, wherein the PEG mol-
ecule of each conjugate is covalently attached to the polymer 
matrix, wherein the LMWH molecule of each conjugate is 
covalently attached to the PEG molecule of the same conju-
gate, and wherein the LMWH molecule of each conjugate is 
either covalently attached to the second heparin-binding com-
pound or wherein the LMWH molecule of the third conjugate 
is covalently attached and the LMWH molecule of the fourth 
conjugate is noncovalently attached to the second heparin-
binding compound, or (ii) a first and a second PEG molecule 
and a third heparin-binding compound, wherein each PEG 
molecule is covalently attached to the polymer matrix and 
covalently attached to the third heparin-binding compound. 
The hydrogels of the present invention may further com-
prise a second noncovalent crosslink, wherein the second 
noncovalent crosslink comprises a fifth and sixth PEG-
LMWH conjugate, and a PEG-heparin-binding peptide con-
jugate wherein the PEG-heparin-binding peptide conjugate 
comprises two heparin-binding peptides that are covalently 
attached to the PEG molecule of the PEG-heparin-binding 
peptide conjugate, wherein the PEG molecule of each PEG-
LMWH conjugate is covalently attached to the polymer 
matrix, wherein the LMWH molecule of each PEG-LMWH 
conjugate is covalently attached to the PEG molecule of the 
same conjugate, and wherein the LMWH molecule of each 
PEG-LMWH conjugate is noncovalently attached to a differ-
ent heparin-binding peptide of the PEG-heparin-binding pep-
tide conjugate. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a scanning electron micrograph of PEO/LMWH-
dye electrospun fibers. 
6 
FIG. 2 shows Laser Scanning Confocal Microscopy 
(LSCM) images of electrospun PEO fibers (a) transmitted 
light and (b) fluorescence (5 µm scale bar). 
FIG. 3 is an LSCM image of electrospun PEO/LMWH-dye 
5 fibers (5 µm scale bar). 
FIG. 4 is a scanning electron micrograph of electrospun 
PEO/PEG-LMWH-dye fibers. 
FIG. 5 is an LSCM image of PEG-LMWH-dye/PEO elec-
trospun fibers (5 µm scale bar). Dark and colored regions are 
io caused by folds in the surface of the macroscopic sample; not 
by composition variations. 
FIG. 6 shows scanning electron micrographs of (a) PLGA 
electrospun fibers, (b) PLGA/LMWH-dye fibers, and (c) 
PLGA/PEG-LMWH-dye fibers. 
15 FIG. 7 shows LSCM images of electrospun PLGA fibers 
(a) transmitted light and (b) fluorescence (10 µm scale bars). 
FIG. 8 shows LSCM images of electrospun (a) LMWH-
dye/PLGA fibers and (b) PEG-LMWH-dye/PGLA fibers and 
(c) z-stack of PEG-LMWH/PLGA fibers (10 µm scale bars). 
20 FIG. 9 shows bFGF binding on electrospun fibers. Eachbar 
indicates ±standard deviation of the average of three measure-
ments. 
FIG. 10 shows scanning electron microscopy images of 
PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA 
25 fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 
days. 
FIG. 11 shows retention of heparin within electrospun 
matrices as observed by multiphoton microscopy for the 
PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA 
30 fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 
days (10 µm scale bars). 
FIG. 12 shows retention of PEG-LMWH-dye within depth 
of the electrospun matrix after 14 days of incubation in PBS 
as imaged via multiphoton microscopy. 
35 FIG. 13 depicts the release of bFGF from PLGA, LMWH-
Dye, and PEG-LMWH-Dye electrospun fibers after 5 h and 
24 h incubation in PBS. 
FIG. 14 is a digital picture displaying the visual differences 
observed in the binding of bFGF to PLGA, LMWH-Dye, and 
40 PEG-LMWH-Dye electrospun fibers after 5 h and 24 h incu-
bation in PBS. 
FIG. 15 shows the results from the BrdU cell proliferation 
assay. Each bar indicates±standard deviation of the average of 
three measurements. 
45 FIG. 16 provides LSCM images of (a) LMWH/PLGA and 
(b) PEG-LMWH/PLGA fibers (blue) incubated for 8 days 
with MG63 cells (green) (10 µm scale bars). 
FIG. 17 shows (a) CD spectra of PEG-PF4ZIP at different 
concentrations in PBS at 25° C.; (b) Concentration depen- 
5o dence of the MRE for PEG-PF4ZIP at 222 mu. The solid line 
is the best fit. 
FIG. 18 is a schematic of the assembly of hydrogels from 
solutions of the two polymer conjugates. The PF4ZIP is ren-
dered as an oligomerized coiled-coil, as its concentration 
55 (200 µM) under these experimental conditions is two orders 
of magnitude greater than the measured Kd value. 
FIG. 19 depicts storage moduli (closed symbols) and loss 
moduli (open symbols) of the PEG-LMWH/PEG-PF4ZIP 
hydrogels for different molar ratios. The response of 2.5 wt % 
60 of the PEG-LMWH (circles) is shown for comparison. 
FIG. 20 shows plots of normalized storage moduli G' 
(w-0.1 Hz) as a function of HBP (PF4ZIP, ATIII or HIP) to 
LMWH. HIP and ATIII data are adapted from reference 12. 
FIG. 21 is a comparison of storage moduli (closed sym- 
65 bols) and loss moduli (open symbols) of the PEG-LMWH/ 
PEG-PF4ZIP hydrogels (LMWH:PF4ZIP-9:0.5) obtained 
25° C. and 37° C. 
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FIG. 22 shows shear recovery data for PEG-LMWH/PEG-
PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) at 25'C. and 37° 
C. 
FIG. 23 depicts the bFGF release and hydrogel erosion 
profiles of the PEG-LWMH/PEG-PF4ZIP hydrogel 
(LMWH:PF4ZIP=8:1) and the PEG-LMWH/PEG-HIP 
hydrogel (LMWH: HIP 8:2). The errors are derived from the 
average of at least duplicate measurements. 
FIG. 24 shows the release of PEG-LMWH from non-co-
valently assembled hydrogels as indicative of hydrogel ero-
sion. (a) The release profiles of [PEG-LMWH/VEGF] 
(closed) or [PEG-LMWH] (open) hydrogels, in the presence 
of PAE/KDR (•; o) and PAE ( n ; q) or in the absence of cells 
(A; A), respectively. *p<0.001; **p<0.007. (b) The cumula-
tive release of PEG-LMWH at day 4. tp<0.001. 
FIG. 25 shows the release profile of VEGF from non-
covalently assembled [PEG-LMWH/VEGF] hydrogel. 
Release profiles of VEGF in the presence of PAE/KDR (•) or 
PAE (n) cells, and in the absence of cell (A), respectively. 
*P<0.002; **p<0.004. 
FIG. 26 shows the release of VEGF with respect to the 
concentration of VEGFR-2 in PAE/KDR cell cultures. 
FIG. 27 shows the phosphorylated fraction of VEGFR-2 in 
PAE/KDR cultures. (a) Phosphorylation of VEGFR-2 of 
PAE/KDR cultured in the presence of [PEG-LMWH/VEGF] 
(n) and [PEG-LMWH] (•) hydrogels. (b) Phosphorylation of 
VEGFR-2 as a function of cumulative release of VEGF from 
the [PEG-LMWH/VEGF] hydrogel. 
FIG. 28 depicts the proliferation of PAE/KDR and PAE 
cells after 4 days incubation, in the presence of non-co-
valently assembled [PEG-LMWH/VEGF] or [PEG-LMWH] 
hydrogels, respectively. The data are presented as % of con-
trol in which PAEs were cultured in the presence of 2.63 nM 
(100 ng/ml) VEGF in medium. *p<0.003. 
FIG. 29 shows a schematic representation of different 
embodiments involving covalent crosslinking of the hydrogel 
and non-covalent interactions between PEG-HBP, lysozyme, 
or VEGF and the heparinized network. 
FIG. 30 shows a modification of LMWH with maleimide 
groups via the attachment of aminoethylmaleimide (AEM) 
via simple carbodiimide chemistries. 
FIG. 31 shows a four-arm polyethylene glycol) mercap-
toisobutanoate synthesis scheme. 
FIG. 32 shows a time sweep torsion test which shows the 
increase in loss modulus (G", •) and storage modulus (G', 
O) upon swelling a 2 wt % hydrogel with 5 µL 88 mg/ml 
lysozyme solution at 100 minutes (LMWH:Lysozyme3:1), 
indicated by the starred arrow. 
FIG. 33 shows a frequency sweep torsion test showing an 
increase in higher frequency mechanical properties for swell-
ing a 3 wt % hydrogel with 200 ul 5 mg/ml VEGF solution 
(Hep:VEGF33:1). Circles indicate results from swelling 
with buffer, squares from VEGF. Closed symbols are storage 
modulus (G'), open are loss modulus (G"). 
FIG. 34 shows different crosslink embodiments of the 
present invention. An example of a covalent crosslink com-
prising PEG and LMWH is shown in A. An example of either 
covalent, noncovalent or a crosslink with a mixture of both 
covalent and non-covalent attachments is shown in B. The 
crosslinks in B comprise PEG, LMWH and a heparin-binding 
compound (HBC). An example of a noncovalent crosslink 
comprising PEG, LMWH and heparin-binding peptide is 
shown in C. 
FIG. 35 shows additional example of crosslinked embodi-
ments of the present invention. An example of a covalent 
crosslink comprising PEG and LMWH is shown in D wherein 
a heparin-binding compound is attached to the PEG. Another  
8 
example of a covalent crosslink comprising PEG and a hep-
arin-binding compound wherein a LMWH is attached to the 
PEG. 
5 	 DETAILED DESCRIPTION OF THE INVENTION 
The present invention relates generally to a composition 
and method for the formation of functionalized polymer 
matrices comprising a matrix polymer, a compatibilizing 
to polymer and a biomolecule or other small functionalizing 
molecule. The invention is a novel strategy for the incorpo-
ration of low molecular weight, biologically active molecules 
(or molecules with other activities, e.g. sugars, peptides, 
15 polysaccharides, polypeptides, dyes, electroactive groups, 
etc.) into a fibrous or other matrix. The biological (or other) 
molecules are conjugated to an intermediate molecular 
weight polymer or "compatibilizing polymer" (e.g., but not 
limited to: linear, star, hyperbranched) to allow retention of 
20 the biomolecule in its bioactive form in fibers and other forms 
of polymeric materials (e.g. films, gels, solids, particles, etc.). 
Facile functionalization of electrospun fibers and other mate-
rials with other low molecular weight, bioactive polysaccha-
rides and peptides (and other molecules) is contemplated by 
25 this invention. Such functionalization is important because 
biological processes are controlled via multiple and different 
signaling molecules that have distinct spatial and temporal 
release profiles, and the rate of their release from the fibers 
can be controlled with the technology of this invention. 
30 The invention is currently demonstrated in a preferred 
embodiment comprising a low-molecular-weight-heparin 
(LMWH)-modified star copolymer incorporated into electro-
spun fibers. Attachment of active molecules to intermediate 
35 molecularweight polymers provides effective retention of the 
molecules in the material over time scales relevant for bio-
logical and other potential applications. The choice of inter-
mediate molecular weight compatibilizing polymer will per-
mit control over retention and release rate of the molecule or 
40 other active species. 
Advantages of using a polymer-conjugated biomolecule 
(i.e. polymer conjugate) for incorporation of bioactive moi- 
eties into materials as provided by the invention, in place of 
covalent attachment of the biomolecule to a high molecular 
45 weight polymer used directly in material formation, are sev- 
eral-fold. For instance, they include i) the use of a polymer 
conjugate of the invention does not require a need for the 
development of distinct chemistry relevant for a particular 
molecule/polymer pair used in the material, as any polymer 
50 conjugate could be incorporated into any polymeric matrix; 
ii) the use of a polymer conjugate of the invention does not 
limit the number of molecules that could be incorporated into 
a given material for a given set of chemical transformations; 
iii) in biological applications, the incorporation of biomol- 
55 ecules via the current invention permits their controlled 
release in soluble form; iv) it is easier to control release rate 
and inclusion of multiple molecules at varying ratios/ 
amounts than when a bio (or other) molecule must be 
covalently attached directly to the polymers of the material; 
6o and v) the incorporation of biomolecules into materials via 
this invention allows not only control over release rates, but 
permits facile incorporation of multiple biological (or other 
active) species into materials, and offers the potential for each 
species to have a separate and distinct release rate. 
65 The materials may find application in drug delivery or 
tissue engineering scaffolds to promote tissue repair and/or 
regeneration. They could be useful in other materials in 
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related applications where controlled release of a multiple of 	 acrylates), PEG, PEO, poly(tetrafluoroethylene), poly(gly- 
active ingredients is desired, e.g. biosensors, detoxification, 	 colic add), poly(lactic acid), poly(lactic-co-glycolic acid), 
DNA delivery, etc. 	 poly(caprolactone), poly(3-hydroxybutyrate), poly(ortho 
	
An important, overriding difference of the invention from 	 esters), poly(anhydrides), poly(amido amines), poly(ure- 
the prior art is that it allows for molecules (e.g. growth factors, 5 thanes), poly(dimethyl siloxane), poly(phosphazenes), 
proteins, peptides, and other non-biological molecules, etc.) 	 among others. In addition, collagen, silk, silk-like protein 
to be incorporated into a polymer matrix via compatibiliza- 	 polymers, elastin, elastin-like protein polymers, poly(amino 
tion on of the molecules with the polymer matrix, and that it 	 acids), cellulose acetate, hyaluronic acid, chitosan, fibronec- 
further allows for the controlled incorporation and release of 	 tin, and others, may also be used. 
a variety of different molecules from a polymeric matrix. For 10 	 For applications in which a molecule is to be released in a 
example, in the preferred embodiment (described in more 	 non-biological environment (e.g., water purification, agricul- 
detail in example 1), the incorporation of heparin, and more 	 tural treatments, biosensors, smart fabrics, etc.), any of the 
preferably LMWH, into an electrospun matrix via its attach- 	 above polymers could be employed; specific polymers would 
ment to a star PEG polymer provides increased growth factor 	 be chosen on the basis of the specific application. 
binding to the electrospun matrix. The increased growth fac-  15 Compatibilizing Polymer 
tor binding is due to the conjugation of LMWH to the PEG 	 Any moderate molecular weight polymer, of the chemical 
molecule. The PEG-LMWH molecule takes longer to diffuse 	 compositions of the above matrix polymers, that canbe modi- 
out of the matrix, therefore allowing for more growth factor 	 fied via reasonable chemical means with a biomolecule or 
binding to occur within a given time period as shown by 	 other small functional molecule, moiety, or particle is con- 
comparing the amount of growth factor binding to the PEG-  20 sidered a compatibilizing polymer according to this inven- 
LMWH matrix versus a matrix consisting of LMWH alone 	 tion. Moderate molecular weight preferably comprises, but is 
(See Example 1). 	 not limited to, a molecular weight of approximately 1/2 to Vi000 
	
In the case of electrospun matrices, while there are limita- 	 the molecular weight of the matrix polymer it is bound to, in 
tions to what polymers can be electrospun, there are many 	 such a range that the compatibilizing polymer permits homo- 
possible uses. Solubility of fibers must be controlled, but such 25 geneous incorporation of the biomolecule into the matrix 
control is also possible with this invention as well as matching 	 polymer and sufficiently slows the diffusion-based release of 
of mechanical properties for specific applications that are 	 the biomolecule over timescales relevant for a particular 
accomplished using appropriate choice of polymer, additives, 	 application. Some examples of moderate molecular weight 
and/or processing protocols. 	 polymers that would function effectively as a compatibilizing 
Matrix Polymer 	 30 polymer in this invention include synthetic degradable poly- 
	
Matrix polymers, effective in this invention include but are 	 mers such as poly(glycolic acid), poly(lactic acid), poly(eth- 
not limited to: Nylon 6,6; Nylon 6,10; (other nylons, also), 	 ylene glycol) (PEG), poly(lactide-co-glycoflde), and poly(e- 
polyurethanes, polyacrylonitrile, polyvinyl alcohol, polylac- 	 caprolactone) and others. 
tic acid, polyethylene-co-vinyl acetate, polycarbonate, poly 	 Additional polymers include polymers that could function 
(iminocarbonate)s, polymethacrylates, poly(alkyl meth- 35 as the matrix polymer, such as: poly(acrylic acids), poly(acry- 
acrylic acid)s, polyacrylates, poly(alkyl acrylic acid)s, poly 	 lamides), poly(N-alkyl acrylamides), poly(alkyl acrylates), 
(N,N'-diethylaminoethyl 	 methacrylate), 	 poly(N,N'- 	 poly(3-hydroxybutyrate), poly(ortho esters), poly(anhy- 
dialkylaminoalkyl acrylamides), poly(heylene oxide)/PEO, 	 drides), poly(amido amines), poly(urethanes), poly(dimethyl 
polyethylene terephthalate, polystyrene, polyvinyl chloride, 	 siloxane), poly(phosphazenes), among others. In addition, 
poly vinyl phenol, polyacrylamide, poly(N-alkyl acrylamide) 40 collagen, silk, silk-like protein polymers, elastin, elastin-like 
s, poly lactic-co-glycolic acids, polycaprolactone, poly(2- 	 protein polymers, poly(amino acids), cellulose acetate, 
hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene 	 hyaluronic acid, chitosan, fibronectin, and others, may also be 
fluoride), poly(vinylidene chloride), poly(ethylene glycol)/ 	 used. As the compatibilizing polymer can be functionalized at 
PEG, polyvinyl pyrrolidone, polyethylene, polypropylene, 	 chemical groups located along the length of the polymer 
poly(3-hydroxybutyrate), poly(ortho esters), polyanhy-  45 chain or at the termini of the polymer, many polymers can be 
drides, poly(ether-ester) azopolymers, poly(dimethyl silox- 	 employed. Potential additional polymers include: Nylon 6,6; 
ane), poly(phosphazene)s, other copolymers of the above 	 Nylon 6,10; (other nylons, also), polyurethanes, polyacry- 
homopolymers (e.g. poly(methacrylic acid-co-ethylene gly- 	 lonitrile, polyvinyl alcohol, polyethylene-co-vinyl acetate, 
col), and others. 	 polycarbonate, poly(iminocarbonate)s, polymethacrylates, 
Matrix polymers may also comprise natural polymers, 50 poly(alkyl methacrylic acid)s, polyacrylates, poly(alkyl 
such as collagen, silk, silk-like protein polymers, elastin, 	 acrylic acid)s, poly(N,N'-diethylaminoethyl methacrylate), 
elastin-like protein polymers, poly(amino acids), cellulose 	 poly(N,N'-dialkylaminoalkyl acrylamides), polyethylene 
acetate, hyaluronic acid, chitosan, fibronectin, and others. 	 terephthalate, polystyrene, polyvinyl chloride, poly vinyl 
	
Combination fibers comprising mixtures of different syn- 	 phenol, polyacrylamide, poly(N-alkyl acrylamide)s, poly(2- 
thetic and/or natural polymers can also be prepared. Polymer 55 hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene 
combinations help to optimize solubility and mechanical 
	
fluoride), poly(vinylidene chloride), polyvinyl pyrrolidone, 
properties of the fibers. 	 poly(3-hydroxybutyrate), polyanhydrides, poly(ether-ester) 
	
Composite materials comprising any of the above poly- 	 azopolymers, poly(dimethyl siloxane), poly(phosphazene)s, 
mers and an appropriate inorganic matrix (clays, silicates, 	 other copolymers of the above homopolymers (e.g. poly 
microparticles, etc.) can also be employed as a matrix poly-  60 (methacrylic acid-co-ethylene glycol), and others. 
mer for applications requiring high mechanical strength, such 
	
A preferred compatibilizing polymer for use in this inven- 
as hard tissue engineering applications. 	 tion is poly (ethylene glycol) or PEG. PEG is a linear or 
	
For drug delivery and biological applications, the follow- 	 branched neutral polyether with the chemical formula HO 
ing are particularly preferred: Poly(ethylene), poly(propy- 	 (CH2CH2)n-H. PEG is highly soluble in water and many 
lene), poly(vinyl chloride), poly(vinyl alcohol), polyethyl-  65 organic solvents (e.g., methylene chloride, ethanol, toluene, 
ene-vinyl acetate), poly(enol-ketone), poly(acrylic acids), 	 acetone, and chloroform), and is readily available in various 
poly(acrylamides), poly(N-alkyl acrylamides), poly(alkyl 	 sizes and functionalized architectures (e.g., amino-, car- 
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boxyl-, and sulfhydryl-terminated). Low-molecular weight 
(<100 daltons) PEGS are viscous and colorless liquids, 
whereas high-molecular weight PEGS are waxy solids whose 
melting points are proportional to their molecular weights 
with an upper limit near 67° C. PEG has been found to be 5 
nontoxic and is approved by the FDA for use in drugs (paren-
tals, topicals, suppositories, nasal sprays), foods, and cosmet-
ics. Molecular weights of PEG used in biomedical applica-
tions usually range between a few hundred to 20,000 Da. The 
molecular weight distribution of these PEG polymers is gen- io 
erally low, but the commonly used mono-methyl ethers of 
PEG exhibit broader molecular weight distributions. In solu-
tion, PEG is also a highly hydrated polymer, where each 
monomer (ethylene oxide unit) can bind three molecules of 
water. PEG polymer exhibits a large degree of segmental 15 
flexibility in aqueous solution and it is thought that PEG has 
the ability to influence the structure of several molecular 
layers of more loosely associated hydrating water molecules. 
PEG is valued for its ability to exclude other polymers 
(natural and synthetic) from its presence in aqueous environ- 20 
ment. This exclusion of other polymers is the primary driving 
force behind PEG's ability to reject proteins, from two-phase 
systems with other synthetic polymers, and makes this poly-
mer both nonimmunogenic and nonantigenic. Because of its 
many benefits, PEG is ideally suited for protein modification. 25 
Indeed, PEG is currently considered one of the most success- 
ful techniques to prolong the residence time of protein drugs 
in the bloodstream. There are dozens of examples of PEG-
protein conjugates described in the literature. For example, 
PEG has been considered a tool to enhance drug delivery to 30 
neoplastic tissues such as, for instance, pegylated proteins 
that have been applied in passive tumor-targeting while pegy-
lated monoclonal antibodies or MoAb fragments have been 
investigated as immunotargeting agents. (see, for example 
Sato H., Enzymatic procedure for site-specific pegylation of 35 
proteins, ADVANCED DRUG DELIVERY REVIEWS 54 
(4): 487-504 Jun. 17 2002; Deiters A., et al., Site-specific 
PEGylation of proteins containing unnatural amino acids, 
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 
14 (23): 5743-5745 Dec. 6 2004; Hermanson, Greg T., Bio- 40 
conjugate Techniques, 1s t edition, Academic Press, New 
York, 1996) (All of which are herein incorporated by refer-
ence in their entirety). 
PEG conjugation technology has been used, for example, 
to improve the therapeutic efficacy of recombinant human 45 
proteins because it alleviates many problems associated with 
therapeutic protein formulations. For example, the attach-
ment of PEG to a protein affects its molecular size, charge, 
and receptor-binding capabilities, which can serve to 
decrease the conjugate's overall rate of clearance from the 50 
body. Also, by sterically shielding the protein domains sus-
ceptible to proteolytic attack, PEG decreases the protein deg-
radation that causes protein biological inactivity. Finally, by 
sterically masking a therapeutic protein's immunogenic/an-
tigenic determinants, PEG conjugation commonly results in 55 
conjugates that are nonimmunogenic and nonantigenic. The 
result of changes in the parental protein's characteristics by 
PEG almost invariably increases the plasma half-life and 
resistance to proteolytic degradation, and decreases immuno-
genicity and antigenicity of the resultant PEG-protein conju- 60 
gate. Although PEG is generally considered to be non-immu-
nogenic, its parenteral administration has been found to 
stimulate the production of antibodies. 
Small Functioning Molecule 
Small functioning molecules according to this invention 65 
include, but are not limited to, biomolecules and functional 
molecules such as peptides, sulfated peptides/polypeptides, 
peptides/polypeptides with other functionalization/modifica-
tions, peptides/polypeptides containing non-natural amino 
acids, polypeptides (natural AA, sulfated, non-natural AA, 
other modified side chains, etc.), protein fragments, proteins 
(e.g., growth factors, growth hormones, cytokines, insulin, 
etc.), enzymes, saccharides, oligosaccharides, polysaccha-
rides, small molecule drugs (e.g., doxorubicin, aspirin, adria-
mycin, tetracycline (antibiotic), chloroquine (antimalarial), 
tamoxifen, and other small molecule drugs that can be chemi-
cally conjugated to a polymer), dyes, organics, metals, and 
nanoparticles and nanomolecules. 
One particularly interesting biomolecule is heparin. Hep-
arin is a highly sulfated glycosaminoglycan that binds or 
interacts with growth factors such as fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), heparin-
binding epidermal growth factor (HBEGF), transforming 
growth factor-(3 (TGF-(3), nerve growth factor (NGF), and 
others. Growth factor agonists and antagonists also bind or 
interact with heparin. Those having skill in the art are clearly 
aware that growth factors are important for controlling cellu-
lar activities such as cell growth and proliferation. The incor-
poration of heparin in the electrospun matrix is of functional 
importance owing to heparin's role as a binding site for many 
growth factors; sulfated peptides may have similar activity 
and would therefore also be useful for similar reasons. For 
example, the binding of growth factors to glycosaminogly-
cans in the ECM is essential for storage, release, and preser-
vation of the bioactivity of the growth factor. Heparin prima-
rily serves to immobilize growth factors until release but is 
also known to control their mitogenic activity, and in several 
cases, serves as a cofactor to promote binding of the growth 
factors to their receptors. Heparin is also known to regulate 
the growth of fibroblast and endothelial cells when combined 
with heparin-binding growth factors. For example, heparin 
has been reported to have been incorporated into a chitosan 
hydrogel where it was found to induce neovascularization in 
vivo and enhanced the activity of acidic fibroblast growth 
factor (aFGF) and basic fibroblast growth factor (bFGF) and 
stabilized the growth factors in vitro. A variety of other 
reports also confirm the benefits of including heparin in a bulk 
hydrogel matrices, such as those comprising fibrin, PEG, 
collagen, hyaluronic acid, and synthetic polymers, and the 
extension to a fibrous matrix may provide additional struc-
tural advantages for producing materials that mimic the 
ECM. Incorporation of biomolecules such as heparin, into a 
polymer matrix allows for the exploitation of heparin's affin-
ity for growth factors as a strategy to deliver them from a 
fibrous ECM-mimetic matrix. Those having skill in the art 
understand that heparin binds a variety of proteins with dis-
parate function. It is contemplated that any such protein 
would be a candidate for use in this invention. 
Method of Formulating Functionalized Polymers 
Some methods for processing polymers into a given form 
that can be applied in the invention for producing polymeric 
matrices capable of controlled release of the compatibilizing 
polymer/biomolecule conjugates include, for example, 
crosslinking of a polymer to form a hydrogel network can be 
employed; any method for crosslinking polymers can be 
applied for formation of the crosslinked network, using stan-
dard initiators or at least trifunctional monomers; standard 
free radical initiators include thermal initiators, redox initia-
tors, photoinitiators; the inclusion of a bifunctional vinyl 
molecule with appropriate vinyl monomers would produce 
crosslinked networks of the vinyl matrix polymers. 
Additionally, noncovalent methods of producing a 
crosslinked network could be employed. Such interactions 
include but are not limited to ionic crosslinking (e.g. alginate 
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crosslinking via interaction with divalent cations, layer-by-
layer deposition of polyelectrolytes, etc.), protein-protein 
interactions, peptide-saccharide interactions, saccharide-sac-
charide interactions, self-assembly of peptidic molecules, 
and antibody-antigen interactions. The pore size of the 
crosslinked network should be smaller than the size of the 
compatibilizing polymer/biomolecule conjugate in order to 
permit release of the biomolecule to be delayed via its con-
jugation to the compatibilizing polymer. 
Any method of forming different three-dimensional par-
ticles and structures could also be applied in the current 
invention. For example, emulsion (or inverse emulsion) poly-
merizations, crosslinking (in colloidal suspensions, micellar 
or liposomal solutions, or emulsions), or spray crosslinking 
can be used to form particulate and nanoparticulate polymers. 
Crosslinking of monomer solutions in a mold or microfluidic 
channel permits the construction of a matrix of essentially any 
shape/size. Films cast of the monomer solutions (e.g., via 
spincoating, doctor blade application, dipcoating, etc.) can 
also be produced via crosslinking by any of the above mecha-
nisms or via simple casting/drying of a non-water soluble 
polymer. 
Electrostatic fiber spinning, or "electrospinning," is a pre-
ferred process for this invention. Electrospinning is a process 
by which superfine fibers, ranging from approximately 10 
nanometers to about 10 microns in diameter, are formed. The 
resulting electrospun fiber web has a high specific surface 
area that is beneficial in a wide variety of technologies due to 
the small fiber diameter and its porous structure. A high 
voltage source is used during the electrospinning process to 
generate an electrically charged jet of polymer solution or 
melt expelled from a device such as a pipette. This process is 
then followed by a drawing of the resulting filaments as they 
solidify or coagulate. Electrospinning provides a simple 
approach for production of solid, as well as hollow, one-
dimensional nanofibers from a variety of starting materials. 
To date, dozens of synthetic or natural polymers, melts, and 
polymer blends have been successfully spun using the elec-
trospinning process. (see, for example, Shin et al., Biomate-
rials 2003, 24, 4353-4364; Sukigara et al, Polymer 2003, 44, 
5721-5727 (Frank Ko); Li et al, J. Biomed. Mater. Res. 2002, 
60, 613-621 (Frank Ko); 7in et al., Biomacromolecules 2002, 
3, 1233-1239 (David Kaplan); Tin et al., Biomaterials, 2004, 
25, 1039-1047 (David Kaplan); Farach-Carson, M. C.; Wag-
ner, R. C.; Kiick, K. L., Extracellular Matrix Structure, Func-
tion, and Applications to Tissue Engineering, CRC Biomedi-
cal Engineering Handbook, CRC Press, New York, 2004; 
Huang et al., Composites Science and Technology 2003, 63, 
2223-2253) (All said references are herein incorporated by 
reference in their entirety). A broad range of electrospun 
materials have been published and include synthetic poly-
mers with electrical properties ranging from non-conducting 
polyurethane to conducting polyaniline, in addition to natural 
polymers such as collagen and silkworm silk. There is also 
much recent work on nanofibers electrospun from biocom-
patible or biodegradable polymers for bioengineering appli-
cations. The fibers may be made from a polymer solution via 
an electro spinning process as described in Reneker, U.S. Pat. 
Nos. 4,323,525, 4,689,525, US 20030195611, US 
20040018226, and US 20010045547, which are incorporated 
herein by reference in their entirety. The specific types of 
polymers that may be produced in fiber form via the electro-
spinning process include those listed in Huang, US 
20030195611, US 20040037813, US 20040038014, US 
20040018226, US20040013873, US 2003021792, US 
20030215624, US 20030195611, US 20030168756, US 
14 
20030106294, US 20020175449, US20020100725 and 
US20020084178 all of which are herein incorporated by ref-
erence in their entirety. 
When constructing electrospun fibers forbiomedical appli- 
5 cations, certain material considerations must be acknowl-
edged. Some minimal properties of a drug delivery system are 
that the material must be non-immunogenic, degradable with 
non-toxic products, able to be excreted from the body, and 
deliver therapeutic molecules in a controlled and predictable 
i o manner. Manufacturing time and complexity, along with han-
dling, must also be considered. In compliance with these 
requirements, matrix polymers such as PEO and PLGA serve 
as excellent candidates for fabrication of the matrix via elec-
trospinning; indeed, the successful use of these polymers in a 
15 variety of tissue engineering and drug delivery applications 
has been documented. Those having skill in the art are famil-
iar with the processes used in tissue engineering and drug 
delivery as required for incorporation in this invention. 
In addition to electro spinning, other traditional methods of 
20 making polymeric fibers can be applied, when possible, to the 
formation of active fibers of larger diameter. Given the choice 
of biomolecule or functional molecule or particle with a par-
ticular matrix polymer would dictate the use of solution spin-
ning, melt spinning, or other spinning protocols. 
25 	 Regarding the attachment of the biomolecule (or other 
small functioning molecules) to the compatibilizing polymer, 
the chemical reactions to be used are unlimited and are chosen 
based on the desired compatibilizing polymer/biomolecule 
combination. Initially, the matrix polymer composition may 
3o be altered for any given desired application and the combi-
nations of matrix polymer/compatibilizing polymer/biomol-
ecule for any application are limited only by the choice of a 
given application, not by the scope of the invention. 
In a preferred embodiment, poly(ethylene glycol) (PEG) 
35 functionalized with low molecular weight heparin (PEG-
LMWH), is fabricated into fibers for use in drug delivery, 
tissue engineering, or wound repair applications. In particu-
lar, a four-arm star PEG with covalently attached LMWH was 
found to be well suited for incorporation into electrospun 
40 fibers with matrix polymers such as PEO and PLGA. Further, 
the use of a PEG-LMWH conjugate proved to have a better 
effect on growth factor binding than when compared to free 
LMWH (see Example 1). 
Interestingly, it was observed that the incorporation of 
45 heparin into the electrospun PEO and PLGA fibers did not 
affect the surface morphology or fiber diameters. The fibers 
produced had diameters ranging from approximately 100 mu 
to 400 mu. Our data indicates that PEG-LMWH conjugates 
can be incorporated into an electrospun matrix at concentra- 
50 tions ranging from 3.5 µg to 85 µg per milligram of electro-
spun fibers, although with greater heparin concentrations in 
the spinning solution, it should be feasible to produce higher 
levels of heparin loading in the fibers. Incorporation of PEG-
LMWH into the matrix permits retention of the heparin for at 
55 least 14 days. Improvements in the binding of basic fibroblast 
growth factor (bFGF) to the electrospun fibers were also 
observed for fibers functionalized with PEG-LMWH over 
those functionalized with LMWH alone. The combination of 
these results suggests the utility for producing electrospun 
60 fibers that are appropriately functionalized for use in bioma-
terials applications. 
Although LMWH was indicated to be incorporated into 
fibers with simple mixing in our investigation, the conjuga- 
tion of LMWH to the star PEG slightly improved the amount 
65 of heparin incorporated into the fiber matrix and permitted a 
significantly improved amount of growth factor binding to 
these matrices, which was suggested to result from an 
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improved retention of heparin in the fibers. If the use of such 
PEG-LMWH conjugates also slows the release of heparin 
over extended periods of time, it will allow for a slower, more 
sustained release of growth factor, which is often required to 
achieve desired biological outcomes. 5 
The conjugation of heparin, and more preferably, LMWH, 
to a relatively short (relative to the matrix polymer molecular 
weight) polymeric chain therefore permits facile functional-
ization of fibers and also allows for retention and significantly 
slowed release of LMWH from the matrix over time. Given io 
the importance of co-presentation of the LMWH with growth 
factors at the growth factor receptor these systems also offer 
the potential advantage of improving growth factor activity 
over systems in which heparin is covalently attached directly 
to the matrix and cantherefore not be co-released with growth 15 
factor. The rate of release of heparin (and therefore growth 
factors) may also be modified via modifications in the poly-
mer conjugate's molecular weight over a wide range, and 
coupled with the greater entanglement likely for flexible 
polymer chains, this may offer advantages over simple incor- 20 
poration of a higher molecular weight heparin in fibers. In 
addition, the controlled incorporation and delivery of other 
and potentially smaller bioactive molecules, such as peptides, 
would also be widely possible via the incorporation of other 
similar PEG bioconjugates into these fibers. The ability to 25 
simply mix various PEG-conjugates in the electrospinning 
solution also offers advantages for creating multifunctional 
fibers. 
The PEG-LMWH molecules used in these electrospinning 
studies have previously been demonstrated to be capable of 30 
sequestering growth factors in hydrogels and delivering them 
in bioactive form to induce proliferation of human umbilical 
vein endothelial cells. The amount of LMWH in these elec-
trospun fiber matrices (3-86 µg) is also similar to that in 
hydrogels produced with these polymers; the hydrogels can 35 
effectively release bFGF for time periods of at least 16 days. 
These results therefore show significant promise for the 
potential of delivering similarly active growth factors from 
electrospun matrices. The additional advantage of the ease of 
mixing combinations of PEG-conjugates in the fibers is also 40 
promising for the facile production of multifunctional, non-
immunogenic matrices for biomaterial applications. 
It was found that LMWH functionalized PEG molecules 
can be easily incorporated into electrospun fibers. These 
fibers have nanometer scale diameters when electrospun 45 
using either PEO or PLGA as carrier polymers. The amount 
of LMWH per mg of fibers can range from 3.5-9.5 µg depend-
ing on the sample examined. Although both LMWH and 
PEG-LMWH can be processed into fibers, the incorporation 
of PEG-LMWH results in functional advantages such as 50 
improved growth factor binding, resulting from improve-
ments in retention of the PEG-LMWH in the fibers over the 
LMWH alone. The PEG-LMWH can be retained in the fibers 
for at least 14 days, in contrast to LMWH, which is almost 
completely released from the fibers after 24 hours. A slower 55 
release of LMWH, and any coupled growth factors, allows for 
drug delivery over a period of time that more closely matches 
the time scales needed for tissue repair or regeneration should 
the fibers be used in biomedical applications. The use of 
electrospinning as the fabrication method forthis biologically 60 
functionalized matrix is preferred due to its ability to allow 
for the incorporation of LMWH, ease of fabrication, fiber 
spinning at a variety of temperatures, and use of small 
amounts of material. The ability to scale electrospinning from 
the laboratory to the industrial scale offers opportunities to 65 
produce matrices for biomaterials applications. The electro-
spun matrix also meets many requirements in its porosity and 
3-D nature to make the fibers suitable for drug targeting and 
tissue engineering applications. Such simple strategies for 
creating electrospun matrices that are both structurally rel-
evant and biologically active could find increased utility in a 
variety of biomedical applications. 
Functionalized Cross-Linked Matrices 
In an alternative embodiment, the invention is directed to 
the use of a functionalized compatibilizing polymer in the 
production of materials in which assembly, mechanical 
response, and biological properties are controlled by protein-
polysaccharide interactions. Such materials are designed to 
mimic the biological environment and find use in the delivery 
of growth factors. 
Specifically, functionalized crosslinked matrices, such as 
hydrogels, capable of assembly by, for example, interactions 
between heparin and peptides, permit the formation of matri-
ces that allow for effective protein delivery. For example, an 
elastic or viscoelastic hydrogel formed by the combination of 
a compatibilizing polymer-LMWH conjugate and a compati-
bilizing polymer-peptide conjugate is a preferred interaction 
contemplated herein. While the use of any compatibilizing 
polymer is contemplated, a preferred compatibilizing poly-
mer for use in this embodiment would include PEG. Also, 
while preferred, it is not necessary that the compatibilizing 
polymer be the same for both the LMWH conjugate and the 
peptide conjugate. 
In this particular embodiment, a hydrogel provides the 
benefits of controlling drug delivery rates by, for example, 
changing the heparin-binding peptide or manipulating the 
hydrogel's physical properties and erosion profiles. 
In a specifically preferred embodiment (more fully 
described in Example 4) a heparin-binding, coiled coil pep-
tide, PF4ZIP, was employed to mediate the assembly of hep-
arinized polymers. Heparin binding peptides (HBP) from 
antithrombin III and the heparin interacting protein have also 
been employed; any heparin-binding peptide with desired 
affinities can be used in the production of materials of this 
kind. Importantly, viscoelastic hydrogels were formed upon 
the association of PF 4ZIP-functionalized star poly(ethylene 
glycol) (PEG-PF4ZIP) with low-molecular-weight heparin-
functionalized star PEG (PEG-LMWH). The viscoelastic 
properties of the hydrogels can be altered via variations in the 
ratio of LMWH to PF4ZIP (or any HBP). Comparison of 
growth factor (bFGF) release profiles with the hydrogel ero-
sion profiles indicates that bFGF delivery from this class of 
hydrogels is mainly an erosion-controlled process and the 
rates of bFGF release can be modulated via choice of HBP or 
via variations in the mechanical properties of the hydrogels. 
Manipulation of hydrogel physical properties and erosion 
profiles provides novel materials for controlled growth factor 
delivery and other biomedical applications. 
Growth Factor-Cross-Linked Matrices 
In even another alternative embodiment, the invention is 
directed to the use of a functionalized compatibilizing poly-
mer to form a crosslinked matrix that comprises the combi-
nation of a compatibilizing polymer-biomolecule conjugate 
and a growth factor, wherein a biomolecule such as LMWH 
functions effectively. In such an embodiment, it is intended 
that the growth factor function as a cross link that eventually 
is removed and drug is released. Removal of the growth factor 
may result from passive release and/or targeted release via 
targeted ligand exchange of the growth factor with specific 
receptors on cell surfaces. The growth factor crosslink may 
also itself be the desired drug, or in certain cases, the PEG-
LMWH polymer may have desired biological effect. 
In a specifically preferred embodiment, PEG-LMWH can 
be mixed with vascular endothelial growth factor (VEGF) to 
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form a viscoelastic hydrogel. Formation of a hydrogel occurs 
as a result of the binding of the heparin-binding VEGF, with 
multiple heparin binding sites, to the PEG-LMWH. While 
VEGF, a dimeric growth factor with two heparin-binding 
sites, is described, other methods for generating growth fac-
tors with multiple heparin binding sites could produce a 
growth factor capable of crosslinking PEG-LMWH polymers 
via noncovalent interactions (e.g. genetic mutation of growth 
factor genes to introduce additional heparin-binding sites in 
the growth factor, conjugation of multiple growth factors to a 
polymer, etc.). Noncovalently crosslinked PEG-LMWH/ 
VEGF hydrogels are capable of releasing VEGF over periods 
spanning at least two weeks, and the release of VEGF (and 
resulting erosion of the network) is also responsive to the 
presence of the cell surface receptors for VEGF. Release of 
VEGF, and erosion of the network, can therefore be coupled 
and made responsive to the cellular environment. VEGF 
released from such assemblies causes increased proliferation 
of porcine aortic endothelial (PAE) cells, which confirms that 
the released VEGF is bioactive. Release of other growth 
factors via similar mechanisms should therefore also be pos-
sible to permit release of multiple, bioactive growth factors. 
Although the invention is illustrated and described herein 
with reference to specific embodiments, the invention is not 
intended to be limited to the details shown. Rather, various 
modifications may be made in the details within the scope and 
range of equivalents of the claims and without departing from 
the invention. 
EXAMPLES 
Example 1 
Electrospinning Functionalized Fibers 
Materials and Methods 
Hydroxy terminated and thiol terminated four-arm star 
poly(ethylene glycol)s (Mn 10,300; Mw 11,300 g/mol and 
M„=10,000; M_-10,800 g/mol, respectively) were pur-
chased from Polymer Source (Dorval, QC, Canada). LMWH 
sodium salt (porcine intestinal mucosa, avg. molecular 
weight 3000 g/mol) was obtained from Sigma (St. Louis, 
Mo.). Alexa Fluor® 350 carboxylic acid, succinimidyl ester 
was obtained from Molecular Probes (Eugene, Oreg.). Sol-
vents and reagents were distilled or purified according to 
standard procedures. 
Synthesis of PEG-LMWH Conjugate 
N-Deacetylation of LMWH. 
LMWH (M, 3000 g/mol) was used inthese investigations. 
In some cases, the LMWH was first separated into a high 
affinity fraction via anionic exchange chromatography on 
diethyl aminoethyl (DEAF) resin. Such fractionation is not an 
absolute requirement, but provides a LMWH fraction with 
higher heparin binding affinity. LMWH was eluted from the 
column via gradient elution in Tris buffer (pH 7.5, 20 mM) 
with sodium chloride concentrations ranging from 0 to 2M. 
The late eluting fraction of LMWH was collected, dialyzed 
against several changes of deionized water (SpectraPor, 
MWCO 1000 Da), and lyophilized prior to use. The fraction-
ated LMWH (250 mg), hydrazine (5.3 g), hydrazine sulfate 
(53 mg), and water (2.3 mL) were added to a heavy duty 
reaction vessel, and the reaction vessel was tightly capped and 
the mixture was stirred at 95° C. for 16 h. After the solvents 
were removed in vacuo, the product was dialyzed using a 
SpectraPor dialysis membrane (MWCO 1000 Da) first 
against 1 M NaCl and finally against water (for each dialysis 
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bath was changed four times after 2, 8, 16, and 24 h) and 
lyophilized to afford a slightly yellowish solid, 153 mg (61% 
yield). 
Synthesis of Maleimide and Alexa Fluor 3508 Functional-
5 ized LMWH. 
To a 10 mL vial were added N-deacetylated heparin (10 
mg), dry dowex 50WX4-200 ion-exchange resin (strongly 
acidic cation), and anhydrous dimethylformamide (DMF, 4 
mL) and the reaction mixture was stirred at room temperature 
io until complete dissolution of heparin was observed. The resin 
was filtered and to the filtrate were added a few drops of 
anhydrous triethylamine and a solution of 4-(N-maleimidom-
ethyl)cyclohexanecarboxylic acid N-hydroxysuccinimide 
ester (0.75 equiv.) (Sigma, St. Louis, Mo.) in anhydrous DMF 
15 (0.3 mL) and the reaction mixture was stirred at 60° C. for 20 
h. To this mixture was added a solution of Alexa Fluor 3508 
carboxylic acid, succinimidyl ester (1 equiv.) in anhydrous 
DMF and the reaction mixture was further stirred at 60° C. for 
20 h. The solvent was removed in vacuo to yield a slightly 
20 yellowish solid, which was redissolved in PBS (pH 6.5, 0.10 
M, 0.15 M NaCI). After the insoluble particles were filtered, 
the filtrate was purified via fast protein liquid chromatogra-
phy (FPLC) equipped with a Superdex 200 gel filtration col-
umn (Amersham, Piscataway, N.7.) using 0.2 M NaCl at 0.5 
25 mL/min as eluting buffer. The heparin containing fractions 
were combined and dialyzed using a SpectraPor membrane 
(MWCO 1000 Da) first with 1 M NaCl and finally with water 
(each dialysis bath was changed four times after 2, 8, 16, and 
24 h) and were then lyophilized to give a slightly yellowish 
30 solid, 4.2 mg; 'H NMR (400 MHz, D 20, 29° C.): d=0.86-1.95 
(10 H, cyclohexyl, m), 3.38-5.43 (72 H, heparin, m), and 6.84 
ppm (2 H, —COCH CHCO , s). 
Synthesis of PEG-LMWH. 
To a 100 mL round bottom flask equipped with a N z inlet 
35 were added maleimide and dye-functionalized LMWH (120 
mg) and PBS (10 mL, pH 6.5, 0.10 M, 0.15 M NaCI) and the 
solution was degassed by bubbling N 2 for 15 min. To this 
solution was slowly added a degassed solution of PBS con-
taining thiol terminated four-arm star PEG (65 mg in 10 mL) 
4o and the reaction mixture was stirred at room temperature for 
2 h. The reaction of the thiol was 96% complete as confirmed 
via analysis with Ellman's reagent. The reaction mixture was 
quenched by adding a solution of N-ethylmaleimide (12 mg) 
in DMF (0.4 mL). The crude product was purified via FPLC 
45 with a Superdex 200 gel filtration column (Amersham, Pis-
cataway, N.7.) at 0.5 mL/min using 0.2 M NaCl as eluting 
buffer. Theproduct isolatedby FPLC was purified via dialysis 
against water (water bath was changed four times after 2, 8, 
16, and 24 h) and lyophilized to give a slightly yellowish 
50 solid, 150 mg; iH NMR (400 MHz, D 20, 29° C.): d-0.86-
1.95 (40 H, cyclohexyl, m), 2.50-2.88 (12 H, 
—COCH2CHC0 , m), 3.38-5.43 (288 H, heparin, m), and 
3.70 ppm (908 H, PEG backbone, CH 2CH20 , s). Inte-
gration of the i H NMR spectrum suggests 73% functional- 
55 ization of PEG with LMWH. 
Electrospinning and Characterization 
Fiber Spinning 
The electrospinning apparatus consisted of a syringe pump 
(Orion SageTM, Fisher, Fair Lawn, N.7.), high voltage supply 
60 (Glassman Series EH, High Bridge, N.7.), 1 mL syringe (Pop- 
per & Sons, New Hyde Park, N.Y.) and a needle (Hamilton, 
Reno, Nev.) with an inner diameter of 0.51 mm. A voltage of 
—12 kV was applied to the tip of the needle. A grounded metal 
sheet was used as the target and was positioned 15 cm from 
65 the tip of the needle for sample collection. The concentration 
of the polymeric solutions varied depending on the carrier 
polymer employed. PEO (BDH Chemicals, Poole, UK, 
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M_-300,000 g/mol) was used at a 10 wt % concentration in 
water and a flow rate of 0.07 mL/min was employed. PLGA 
(Sigma Aldrich, St. Louis, Mo., 75:25, M_-90,000-126,000 
g/mol) solutions were made at a 45 wt % concentration in 
DMF (Fisher, Fair Lawn, N.7.) andrequired a flow rate of 0.26 
mL/hr. 
Characterization 
The electrospun fibers were characterized via field emis-
sion scanning electron microscopy (FESEM) (Hitachi 
S-4700) coupled with the energy dispersive X-ray (EDX) 
(Oxford Inca X-Ray Microanalysis) for elemental analysis of 
electrospun fibers. Laser scanning confocal microscopy, 
LSCM, (Zeiss LSM 510 NLO) was used to observe the loca-
tion of the heparin-bound dye. A fluorescence excitation 
wavelength of 747 mn and a KP685 filter were employed for 
these experiments. An oil immersion type Plan-Neofluar 40x/ 
1.3 oil DIC (differential interference contrast) was used to 
obtain images in FIGS. 4, 5, 9,10,12 and a Plan-Apochrornat 
63x/1.4 oil Ph3 (phase contract the 3 denotes a specific 
condenser lens used) was used to collect the image in FIG. 7. 
A z-series was made for each sample at 0.8 or 1.0 µm sections. 
Toluidine Blue Assays 
To determine the amount of heparin in the electrospun 
fibers, a common colorimetric method employing toluidine 
blue was used. A toluidine blue solution was made by dis-
solving 25 mg toluidine blue (Sigma Aldrich, St. Louis, Mo.) 
and 1 g NaCl in 0.49 mL of 37% HCl and 50 mL of water. The 
toluidine blue that reacts with the heparin is removed from 
solution via extraction with hexanes (5 mL). The amount of 
unextracted toluidine blue remaining in the aqueous solution 
was determined by measuring the absorbance at 631 mn and, 
by difference, provides an estimate of the heparin concentra-
tion. 
Samples were prepared by adding 1 mg of electrospun 
fibers to a solution consisting of 0.8 mL of toluidine blue 
solution and 2.5 mL of 0.1 % NaCl. The test tube was vortexed 
and 5 mL of hexanes was added with additional vortexing. 
After 10 minutes, 120 µL of the toluidine blue solution was 
transferred into a cuvette and absorbance measurements were 
taken. The control samples consisted of 1 mg of either PEO or 
PLGA fibers, without heparin, to adjust for the amount of 
toluidine blue that may adhere to the fibers. Measurements 
were performed in duplicate. 
Growth Factor Binding 
Growth factor binding assays were employed to determine 
if the LMWH and PEG-LMWH electrospun samples were 
able to bind bFGF. All growth factor experiments were com-
pleted at room temperature in 24-well polystyrene assay 
plates (Corning Inc., Corning, MY.), blocked with 3% bovine 
serum albumin (BSA) (Sigma Aldrich, St. Louis, Mo.) in 
phosphate buffered saline (PBS) (Invitrogen, Carlsbad, 
Calif.). All electrospun samples were washed with PBS at 
room temperature. Samples were placed in the wells and 
incubated with 500 µL of a solution of basic fibroblast growth 
factor (bFGF, R&D Systems, Minneapolis, Minn., 10 ng/mL 
in PBS) for 2 h. After seven washes with 0.05 wt % Tween20 
in PBS (PBS-T), 500 µL of a solution of bFGF antibody was 
added (R&D Systems, Minneapolis, Minn., 2 µg/mL in PBS) 
and incubated for 2 h. The samples were washed seven more 
times with PBS-T. The samples were then incubated for 30 
min. in a 500 µL solution consisting of 1 µL horseradish 
peroxidase conjugated NeutrAvidin (Pierce, Rockford, Ill., 1 
mg/mL), 8 mL PBS, and 2 mL SuperBlockTM Blocking 
Buffer (Pierce, Rockford, Ill.). The fibers were then washed 
seven times with PBS-T and incubated in 500 µL of TMB 
substrate solution (Pierce, Rockford, Ill.) for 10-12 mins. 
Absorbance at 450 mn was measured. All absorbance values 
20 
were normalized with respect to a well treated with bFGF and 
antibody, as explained previously, but without any electro-
spun fibers. The growth factor binding assay was completed 
three times and the average values are reported. 
5 Results 
Electrospinning Physical Mixtures (1:4) of LMWH and PEO 
A 1:4 LMWH to PEO mixture (25 mg LMWH and 100 mg 
PEO) was dissolved in water and electrospun. The fibers 
resembled typical electrospun PEO fibers with an approxi-
mate diameter of 100-400 nm and were slightly beaded. The 
presence of microspheres with an average diameter of 1-5 µm 
was also observed. Two control solutions were made. One 
control consisted of a 10 wt % PEO/H 20 and the other a 10 wt 
15 % LMWH/H2O. The 10 wt % PEO/H 20 solution electrospun 
to form PEO fibers with a diameter of 100-400 nm. The fibers 
were circular in their shape and contained beads (200-600 nm 
in diameter) but no microspheres were observed. The 10 wt % 
LMWH/H2O control did not form fibers or microspheres, 
20 which is almost certainly due to the lack of entanglements in 
the negatively charged LMWH (3,000 g/mol). Attempts to 
electrospin higher MW heparin (12,000 g/mol) also failed for 
similar reasons. 
Toluidine blue assays were performed on the electrospun 
25 physical mixtures of PEO and LMWH to determine if 
LMWH was present in the sample. It was found that 86 µg 
(+/-7.15) of LMWH was present per mg of electrospun 
fibers. The presence of LMWH indicated by the toluidine 
blue assay is consistent with the presence of LMWH in the 
30 
matrix. 
EDX was employed to determine the location of the hep-
arin in the fiber matrix via detection of sulfur on the sulfated 
heparin; the results of the EDX analysis are outlined in Table 
35 1. The presence of aluminum in the sample is due to the 
aluminum SEM mount used to hold the fibers. PEO fibers 
served as a control for this experiment; EDX detected 46% C, 
5% O, and 49% Al in the PEO fibers, consistent with the 
composition of PEO. The significant amount of C detected 
40 was most likely to due to carbon adhesive tab that was used to 
secure the fibers for imaging. A thin film was cast of 10 wt % 
LMWH/H2O and used as the second control The atomic 
composition detected via EDX was 23% C, 40% O, 17% S, 
and 18% Na, consistent with the presence of LMWH in the 
45 sample (sodium is the counterion for the LMWH used in these 
studies). The 1:4 LMWH: PEO electrospun sample was tested 
in three different areas: the fiber portion, bead portion, and the 
microsphere. The fibers contained 42% C, 5% O, and 59%Al. 
Since no sulfur or sodium was detected, the results suggest 
50 that either the fiber section of the matrix consists of primarily 
PEO or that the concentration of sulfur is too low for detection 
via EDX. Generally, the lower limit of detection for EDX is 
approximately 1%, so it is possible that the LMWH may be 
55 incorporated into the fibers but at a concentration much lower 
than 1%. The beaded section of the matrix was found to 
contain 61 % C, 13% O, 26%Al, and 0.3% S. The detection of 
the sulfur indicates that LMWH is present, at low concentra-
tions, in the beaded areas of the electrospun mat. The micro- 
60 spheres were shown to contain 73% C, 20% O, 4% Al, 1.2% 
S, and 1.4% Na. The presence of sulfur and sodium imply that 
LMWH is present in the microspheres at higher concentra-
tions than found in the beaded sections of the mat. The EDX 
results are consistent with the expected composition of the 
65 fibers, and the varying amount of sulfur in the different 
regions suggests that LMWH is not uniformly incorporated 
into the fibers via simple mixing. 
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TABLE 1 
Average elemental composition of electrospun samples as determined 
by EDX (compositions are represented in atomic weight percent) 
Sample C (% 0(%) 	 At (% S(%) Na (% 
PEO Fibers 46 ± 14.7 5.0 ± 1.15 	 49 ± 14.2 ND* ND 
LMWH Film 23 ± 1.63 40 ± 2.16 	 ND 17 ± 1.41 18 ± 2.50 
1:4 LMWH:PEO 
fiber section: 42 ± 9.02 5.0 ± 0.577 	 59 ± 18.9 ND ND 
bead section: 61 ± 2.65 13 ± 2.31 	 26 ± 4.51 0.3 ± 0.025 ND 
microsphere 73 ± 2.52 20 ± 5.13 	 4.0 ± 1.66 1.2 ± 0.48 1.4 ± 0.13 
section: 
22 
*ND = not detected 
Electrospinning Dye-Labeled LMWH with PEO 
To visually map the location of the LMWH throughout the 
electrospun mat, a fluorescent dye, Alexa Fluor 3508, was 
covalently attached to LMWH, and the fibers were analyzed 
via LSCM; observation of fluorescence permits direct obser-
vation of the presence and location of LMWH throughout the 
electrospun matrix. PEO (10 wt %) was mixed with Alexa 
Fluor 3508-labeled LMWH (0.2 wt %) and electrospun. FIG. 
1 shows resulting fibers with diameters of approximately 
100-200 mu, with a few very large beads approximately 6 µm 
in diameter. 
The fibers were then analyzed via LSCM to determine if 
the LMWH-dye molecules were incorporated into the matrix 
and to determine their distribution in the matrix. Electrospun 
PEO fibers were used as a control; results for the control are 
shown in FIG. 2. FIG. 2a shows data in reflection mode and 
confirms that fibers were present on the glass coverslip. FIG. 
2b shows two small areas of fluorescence that are likely 
impurities in the PEO or dust in the sample, but confirms the 
complete lack of background fluorescence in the PEO fibers. 
FIG. 3 presents LSCM data for electrospun fibers of the 
LMWH-dye/PEO mixture. The results demonstrate the fluo-
rescence of the fibers, indicating the presence of LMWH. In 
contrast to SEM and EDX results, the LSCM results also 
suggest that the LMWH-dye is present not only in the beaded 
sections of the matrix, but also in the fiber regions. FIG. 3 
shows the fluorescence of the fibers due to LMWH-dye incor-
poration. Z-stack images were also taken (not shown) to 
ensure that the LMWH-dye is present throughout the entire 
depth of the matrix and is not localized in any one area. Due 
to the LSCM limit of resolution, approximately 200 mu, the 
exact location of the heparin within each individual fiber is 
unknown. However, all LSCM images indicate that LMWH 
is present throughout the depths of the electrospun matrix, 
suggesting a fairly uniform dispersion of LMWH. Measure-
ment of LMWH via toluidine blue assay confirmed the pres-
ence of approximately 4.3 ltg (+/-0.923) of LMWH per mg of 
electrospun sample. A direct comparison cannot be made 
between the amount of LMWH in this sample and the amount 
in the physical mixtures of LMWH and PEO due to differing 
amounts of LMWH in the initial solutions. Nevertheless, 
these results suggest the opportunities for facile incorporation 
of bioactive polysaccharides into electrospun matrices. 
Incorporation of PEG-LMWH-Dye in PEO for Electrospin-
ning 
LMWH was covalently attached to the termini of a 4-arm 
star PEG and evaluated for its incorporation into an electro-
spun matrix. PEG-LMWH-dye (0.2 wt %) was mixed with 
PEO (10 wt %) in water. The electrospun fibers from this 
solution were analyzed via FESEM, with results shown in 
FIG. 6. As is shown in FIG. 6, the resulting fibers were  
15 
100-300 mu in diameter with the presence of microspheres 
(1-3 µm). The morphology of the PEG-LMWH fibers was 
very similar to those produced from the earlier samples with 
20 
free LMWH. In both electrospun mats, fibers are in the 
nanometer size range and the onset of bead formation is 
observed by the roughness of the fibers (see FIGS. 1 and 4). 
The fiber matrix was then analyzed via LSCM to confirm 
that the PEG-LMWH-dye molecule was incorporated in the 
25 electrospun fibers; representative results are shown in FIG. 5. 
Similar to the results in FIG. 3, the data shown here also 
indicate that the fibers are evenly fluorescent across the 
matrix, showing that the PEG-LMWH was evenly distributed 
in the PEO fiber matrix. These fibers were found to contain 
30 3.5 µg (+/-0.397) of heparin per mg of electrospun fibers. 
These results indicate a slight improvement in LMWH incor-
poration in comparison to the LMWH/PEO fibers, and may 
suggest that PEG-LMWH permits the incorporation of 
slightly more heparin than in the fibers produced using free 
35 heparin. 
Changing the Matrix Polymer 
Multiple polymers could be used as the matrix polymer. 
PLGA was chosen as an alternate carrier polymer for the 
40 
LMWH systems due to the success of PLGA in biomaterial 
applications. PLGA/DMF (45 wt %) was electrospun with 
LMWH-dye (0.2 wt %) and also with PEG-LMWH-dye (0.2 
wt %). Due to differences in molecular weight and viscosity, 
the concentration of carrier polymer is different than those 
45 used for PEO electrospinning, but all other processing con-
ditions remained the same. The electrospun PLGA fibers are 
approximately 400-800 nm in diameter, (FIG. 6a). SEM 
revealed that fiber morphology was not affected by the incor-
poration of LMWH-dye or PEG-LMWH-dye, (FIGS. 6b and 
5o 6c). 
LSCM showed that the PLGA electrospun mat, shown in 
FIG. 7a under transmitted light, does not fluoresce to any 
significant extent. As encountered previously with PEO 
fibers, there is a small area of fluorescence in FIG. 7b, which 
55 is likely due to polymer impurities or dust on the sample. The 
images shown in FIG. 8 reveal that both LMWH-dye and 
PEG-LMWH-dye were incorporated into the PLGA matrix 
and z-stack LSCM images confirm that the heparin is present 
throughout the depths of the matrices. The toluidine blue 
6o assay indicated that there is approximately 8.41 ltg (+/-
0.532) of LMWH present per mg of electrospun LMWH/ 
PLGA sample. The PEG-LMWH/PLGA sample contained 
9.50 ltg (+/-0.382) of LMWH per mg of electrospun fibers. 
The results of the FESEM, LSCM, and the toluidine blue 
65 assays suggest that the carrier polymer can be changed with-
out affecting the incorporation of heparin or fiber morphol-
ogy. 
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Example 2 	 are observed. After 14 days incubation in PBS, the PEG- 
LMWH-dye fibers still exhibit a moderate level of fluores- 
Growth Factor Release Assays of Electrospun Fibers 	 cence in comparison to the LMWH-dye fibers, which show 
An ELISA format was employed to characterize the bind- 	 minimal signs of fluorescence. The differences in the amount 
ing of bFGF in a series of samples: a blank well, PLGA fibers 5 of LMWH retained in the fibers were also observed through- 
alone, LMWH/PLGA fibers, and PEG-LMWH/PLGA fibers. 	 out the depth of the matrix, as confirmed via z-stack images 
Growth factor release studies were performed using a Quan- 	 (see FIG. 12 for a representative z-stack image of PEG- 
tikine Human FGF Basic Kit (R&D Systems, Minneapolis, 	 LMWH-dye fibers after 14 days incubation in PBS). 
Minn.). Incubation of the growth factor was completed using 	 bFGF release experiments were conducted with the 0.2 wt 
a 24-well polystyrene plate (Corning Inc., Corning, N.Y.) and io % LMWH-dye and PEG-LMWH-dye fibers over a 24 h 
transwell membranes (Fisher Scientific, Atlanta, Ga., 8 µm 	 period. As seen in FIG. 13, the release of LMWH-dye, PEG- 
pore size) were used to secure the fibers during the release 	 LMWH-dye, and the PLGA control all exhibited less than 1 % 
study. The plate, membranes, and fibers were blocked with 	 release of bFGF. This study was repeated to monitor the 
3% BSA (Sigma Aldrich, St. Louis, Mo.) in PBS (Invitrogen, 	 release over a 21 day period, assuming that the low release 
Carlsbad, Calif.) overnight. All samples were washed three 15 rates were due to the short incubation time of 24 h. However, 
times with PBS at room temperature and then incubated with 	 the 21 day release consistently showed less than 1% bFGF 
4 µL bFGF (R&D Systems, Minneapolis, Minn., 2.5 µg/mL in 	 release for all samples. Similar results were obtained in 
PBS) for 2 h at 4° C. The fibers were then transferred to the 	 release studies conducted at 37° C. In order to determine if 
transwell membrane and 1 mL of PBS was added and incu- 	 any bFGF remained in the electrospun matrices after these 
bated at 4° C., unless otherwise indicated, for a specified 20 release studies, a binding study was completed on the 0.2 wt 
amount of time. The wells were replenished with fresh PBS 	 % heparin-containing fibers after 5 h and 24 hrelease in PBS. 
after each aliquot was removed. The amount of bFGF present 	 FIG. 14 is a digital picture showing the visual differences in 
in the matrix was determined via use of a standard spectro- 	 the binding of bFGF to the fibers. The more intense the blue 
photometric immunochemical assay following the protocols 	 color, the more bFGF present. This picture clearly shows 
of the manufacturer (R&D Systems, Minneapolis, Minn.). 25 dramatic differences in binding to the PEG-LMWH fibers 
Slight variations of the procedure could be necessary depend- 	 versus LMWH and PLGA only fibers. However, more 
ing on the composition of the matrix. 	 LMWH is present in the PEG-LMWH-dye fibers. This sug- 
The optical density measurements, at a wavelength of 450 	 gests that either 1) more bFGF is retained in the PEG- 
mu, resulted in the following absorbance values relative to the 	 LMWH-dye fibers due to the reduced diffusion times of the 
control (increasing absorbance values correlate with increas-  30 PEG-LMWH-dye complex or 2) all fibers may contain simi- 
ing growth factor binding): PLGA fibers 1.59 (+1-0.055), 	 lar amounts of residual bFGF but the PEG-LMWH-dye fibers 
LMWH/PLGA fibers 2.46 (+/-0.146), and PEG-LMWH/ 	 protect the structure of the bFGF and, thus, apparently more 
PLGA fibers 3.59 (+/-0.106). FIG. 9 shows that there are 	 growth factor is detected by the immunochemical assay. 
significant differences in bFGF binding between the LMWH/ 
PLGA and PEG-LMWH/PLGA fibers, despite the fact that 35 	 Example 3 
the toluidine blue assays show that the two matrices contain 
similar amounts of LMWH after electrospinning. Since both 
	
Cell Proliferation Assay 
the LMWH and PEG-LMWH samples began with similar 	 The PEG-LMWH/PLGA, LMWH/PLGA, and PLGA 
amounts of heparin but did not exhibit the same level of bFGF 
	
fiber matrices were tested to determine if there were any 
binding, these data suggest that the PEG-LMWH may be 4o differences in the ability of the membranes to affect cellular 
retained in the electrospun fibers more effectively than 	 proliferation of MG63 (human osteosarcoma) cells. PLGA, 
LMWH alone. FESEM characterization of the electrospun 	 LMWH/PLGA, and PEG-LMWH/PLGA electrospun mem- 
membranes after the growth factor binding assay revealed 
	
branes were sterilized under UV light for 4 h and incubated in 
that the PLGA fibers exhibited no visible signs of degradation 	 1.5 mL Dulbecco's Modified Eagle Medium (DMEM) con- 
during the time frame of the growth factor binding study 45 taining 5% (v/v) fetal calf serum (FCS), bFGF (10 ng/mL), 
(FIG. 10, parts a and b). This observation corroborates the fact 	 penicillin (100 U/mL) and streptomycin sulfate (100 µg/mL) 
that differences in growth factor binding likely result from 	 for 2 h. The membranes were then washed 2-3 times with 
differential LMWH retention rather than from variations in 	 sterile PBS. All membranes were incubated in bFGF (15 
fiber degradation between samples. These electrospun mem- 	 ng/membrane) prior to the cell proliferation assay. The mem- 
branes were also incubated in PBS for an additional 1 day, 3 5o brans were then placed in 24-well tissue culture dishes con- 
days, and 14 days to determine if any fiber degradation 	 taining an MG63 cell (2x105 cells/mL, American Type Cul- 
occurred (FIG. 10, parts c-h). These SEM images show that 	 ture Collection, Manassas, Va.) suspension in DMEM 
there are no visible signs of fiber degradation for the time 	 supplemented with 5% (v/v) FCS. The plates were shaken 
period studied in this investigation. 	 every 30 min for 4 h. The scaffolds were then transferred to a 
Characterization of the fibers after completion of the 55 new 24-well plate and incubated in DMEM containing 1% 
growth factor binding assays was conducted via multiphoton 	 (v/v) FCS at 37° C. in an atmosphere of 95% air and 5% CO 2 . 
microscopy FIG. 11, parts a and b, shows the LMWH reten- 	 Culture medium containing 1 % (v/v) FCS was changed every 
tion within the electrospun fibers after the growth factor 	 3 days. Cultures were terminated on days 1, 3, 6, 9, 12, and 15. 
assay, or 6 h of PBS incubation. After only 6 h in PBS, slight 	 MG63 proliferation was determined by immunodetection of 
differences in the amount of LMWH within the fibers were 6o bromodeoxyuridine (BrdU) incorporation (Cell Proliferation 
observed via multiphoton microscopy; these differences were 	 ELISA Biotrak System, Amersham Biosciences, Piscataway, 
much more pronounced with an additional 24 h incubation in 	 N.7.), according to the manufacturer's instructions. Cells 
PBS (FIG. 11, parts c and d). In FIG. 11, parts e-h, the 	 seeded on the electrospun membranes were labeled with 
multiphoton images are shown in fluorescence and reflection 	 BrdU and then incubated with peroxidase-labeled anti-BrdU 
mode. This was necessary due to the small amount of fluo-  65 antibody. Excess anti-BrdU antibody was removed by wash- 
rescence in the samples in order to prove that fibers are 	 ing the membranes with washing buffer in a vortex mixer. The 
present. In FIG. 11, parts g and h, the most visible differences 	 membranes were then incubated in TMB substrate to produce 
US 8,367,639 B2 
25 
a colored solution. A plate reader was employed with detec-
tion at 450 nm to obtain optical density measurements. Three 
fiber membranes per sample were tested each day. 
FIG. 15 illustrates the differences in cellular proliferation 
on PLGA, LMWH/PLGA, and PEG-LMWH/PLGA mem-
branes. It was expected that cell proliferation would occur on 
all the samples tested due to the biocompatibility of PLGA, 
however, our interest was to determine which samples 
reached maximum cell proliferation first. The most signifi-
cant differences were observed on day 6 where PEG-LMWH 
membranes exhibit significantly higher cell proliferation and 
therefore reached saturation before LMWH/PLGA or PLGA 
alone. FIG. 16 shows LSCM images of the cells (dyed green 
using a syto 13 stain) on electrospun LMWH or PEG-LMWH 
fibers (fluorescing blue due to the dye attached to the hep-
arin). FIG. 16b shows that more cells are present on the 
PEG-LMWH/PLGA matrix and the image suggests that more 
cells penetrate the PEG-LMWH matrix (FIG. 16b) when 
compared to the LMWH fibers alone (FIG. 16a). These 
images illustrate the differences in cellular proliferation due 
to the presence of PEG-LMWH. Based on the results of this 
cellular assay it is believed that PEG-LMWH increases the 
rate of cell proliferation in comparison to the other samples 
due to the retention of PEG-LMWH in the matrix that causes 
increased retention and slower release of bFGF, which has 
been suggested in previous results presented in FIG. 14. The 
increased retention of bFGF may support higher cell prolif-
eration rates. Although this was a very preliminary cell study, 
it does indicate that there are functional differences between 
electrospun matrices functionalized with either PEG-LMWH 
or LMWH alone. 
Example 4 
Functionalized Cross-linked Matrices 
Materials 
All materials were obtained and purified as described in 
Example 1. 
Methods 
Synthesis of PEG-LMWH Conjugates 
The synthesis of the PEG-LMWH conjugate exploited in 
hydrogel assembly was conducted via Michael-type addition 
reactions between maleimide functionalized heparin and 
thiol -terminated four-arm star PEG, as described in Example 
1. The degree of LMWH functionalization in PEG-LMWH 
was determined to be 81% via iH NMR spectroscopy. Syn-
thesis of PEG-LMWH-Alexa Fluor 350 was conducted via 
similar protocols as previously described in the art. 
Synthesis of PEG-HBP Conjugates 
All HBPs were prepared on Rink Amide MBHA resin via 
solid phase peptide synthesis with Fmoc-protection using a 
PTI PS3 peptide synthesizer (Protein Technologies Inc, Tuc-
son, Ariz.) and purified via preparative-scale reverse-phase 
HPLC. The PF4ZIP sequence CGGRMKQLED-
KVKKLLKKNYHLENEVARLKKLVG (SEQ ID NO: I) is 
based on a GCN4 coiled coil and mimics the heparin-binding 
domain of human platelet factor 4. The heparin-binding pep-
tides, ATIII and HIP, from antithrombin III (ATIII) and hep-
arin interacting protein (HIP), have sequences of CKbAFAK-
LAARLYRKA (SEQ ID NO:2) and 
CRPKAKAKAKAKDQTK (SEQ ID NO:3), respectively. 
Any heparin-binding peptide of sufficient affinity and appro-
priately slow dissociation (from heparin) would be equally 
applicable for use in these hydrogels. Peptides isolated as 
single fractions via HPLC were characterized via MALDI 
and ESI mass spectrometry. The mass of the purified HBPs 
was confirmed via ESI mass spectrometry. For example, for 
26 
PF4ZIP1  m/z=992.5 [(M+4H)4+, calc'd 992.0] and 
m/z=1322.9 [(M+3H)3+, calc'd 1322.7]. Similar agreement 
between theoretical and observed mass values was observed 
for all other HBPs. 
5 	 The synthesis of the PEG-HBP conjugates utilized in 
hydrogel assembly was conducted via Michael additionreac-
tions between vinyl sulfone-terminated four-arm PEG and 
cysteine-terminated PF4ZIP peptide. 
Characterization 
10 Peptides, PEG-LMWH, and PEG-HBPs were character-
izedvia 1 H NMR spectroscopy and MALDI-TOF Mass Spec-
trometry to determine purity, composition, and degree of 
functionalization. 
Circular Dichroic Spectroscopy (CD) 
15 	 CD spectra were measured at 5° C. to 75° C. on a 7asco 
7-810 spectropolarimeter (7asco Inc, Easton, Md.) equipped 
with a 7asco PTC-424S temperature controller. Samples were 
equilibrated at the desired temperature for 30 minutes prior to 
data collection; equilibration was indicated by the absence of 
20 further changes in the CD signal at longer equilibration times. 
All CD spectra were taken in a 1 mm path length quartz 
cuvette, at wavelengths from 200 to 250 mu. Data points were 
recorded at every nanometer with a 4.0 s response time. The 
concentrations of peptide samples were determined via 
25 amino acid analysis for calculation of mean residue elliptici-
ties. 
Heparin Affinity Measurements 
Heparin-sepharose affinity liquid chromatography was 
performed on an AKTA Explorer FPLC equipped with a 
3o HiTrap Heparin HP column (5 ml, —10 mg heparin/ml gel, 
Amersham Biosciences Corp, Piscataway, N.7.). Surface 
Plasmon Resonance (SPR). SPR sensorgrams were recorded 
on a BiaCore 3000 instrument (Biacore Inc, Piscataway, 
N.7.), employing a high-capacity LMWH surface created on 
35 a commercially available streptavidin-coated chip via treat-
ment with biotinylated LMWH. 
Bulk Rheology Experiments 
Bulk theology experiments of the PEG-LMWH/PEG-
HBP hydrogels were conducted at 25 or 37° C. on a stress- 
40 controlled rheometer (MCR 500, Paar Physica, Anton-Paar, 
Ashland, Va.) with a 25.0 mm diameter parallel plate geom-
etry and a 1 mm gap distance. Strain sweeps were performed 
on samples from 0.001% to a maximum strain of 100% to 
determine the limit of the linear viscoelastic regime (LVE). At 
45 a constant strain of 0.1%, chosen from the LVE, frequency 
sweeps ranging from 0.1 Hz to 100 Hz were conducted. Shear 
recovery experiments were also performed for the PEG-
PF4ZIP-containing hydrogels, and prior to these experiments, 
a baseline oscillation at a constant strain of 0.1% and a con- 
50 stant frequency of 10 Hz was performed, followed by a high-
speed rotation with a 1000 s-1 shear rate for 10 s. The recov-
ery was then measured with a time sweep experiment at a 
constant strain of 0.1% and a constant frequency of 10 Hz. 
Fluorimetry Experiments 
55 	 Fluorimetry experiments to measure the concentration of 
PEG-LMWH-Alexa Fluor 350 (in eroded solutions of PEG-
PF4ZIP-containing hydrogels) were performed using a Fluo-
roMax-3 spectrofluorometer (7obin Yvon Inc, Edison, N.7.) 
with a xenon arc lamp illuminator. Erosion of PEG-LMWH 
60 from other PEG-HBP-containing hydrogels was determined 
gravimetrically. 45 µL of each sample were loaded into a 
cuvette and excited at 346 nm, the excitation spectra peak 
value ofAlexa Fluor 350. The emission spectra peak value at 
442 nm was recorded. Solutions of PEG-LMWH-Alexa Fluor 
65 350 in PBS, with concentrations from 5.42x10-4 wt % to 
4.23x10-6 wt %, were employed for generation of the stan-
dard curve. For erosion profile experiments, the PEG- 
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LMWH-Alexa Fluor 350 was premixed with the PEG- 	 spectra observed exhibit two minima at 208 nun and 222 mu, 
LMWH at a weight ratio of 1:158. The fluorescence 	 demonstrating that PF 4ZIP exists in the coiled-coil state 
intensities of the PEG-LMWH-Alexa Fluor 350 in the eroded 	 under conditions of interest for hydrogel applications. As 
PEG-LMWH were then measured and permitted calculation 	 seen by the appearance of a single minimum at 203 nun in the 
of the percentage of PEG-LMWH eroded from the hydrogels 5 data collected at elevated temperatures, the structure of 
in hydrogel erosion experiments. 	 PF4ZIP reversibly changes to random coil at elevated tem- 
Assembly of PEG-LMWH/PEG-HBP (and PEG-LMWH/ 	 perature. Maximum mean residue ellipticity values at 222 nun 
GF) Hydrogels 	 (MRE222) were measured to be -30,470 deg cm 2 dmol-1 for 
The PEG-LMWH/PEG-HBP hydrogels were formed by 	 the PF4ZIP at 15' C., consistent with reported values ranging 
the interaction between LMWH andPF4ZIP. 5 wt % solutions 10 from -25,000 to -35,000 deg cm 2 dmol-1 for various GCN4 -
of the PEG-HBP in PBS were added directly to 2.5 wt % 	 mimic peptides in PBS at 15° C. 
solutions of the PEG-LMWH in PBS, to afford hydrogel 
	
The conformation of PF4ZIP at various concentrations was 
networks at a final composition of 2.5 wt % total polymer. The 	 also monitored via CD. At all measured concentrations, the 
solutions were mixed in ligand mole ratios of 9:0.5, 8:1, and 	 spectra observed exhibit two minima at 208 nun and 222 mu, 
7.5:2.5 (LMWH:PF4ZIP dimer); other ligand mole ratios are 15 demonstrating the helical character of PF 4ZIP under these 
also useful for hydrogel assembly. For VEGF-crosslinked 	 conditions. The measured MRE222 for a solution of 56 µM 
hydrogels, an 8 wt % solution of PEG-LMWH in PBS is 	 PF4ZIP in PBS is -24,580 deg cm2 dmol-1 , which is consis- 
mixed with varying amounts of solid VEGF (0.1-20 µg) to 	 tent with the value reported for 40-60 µM PF 4ZIP in 3 mM 
afford a self-supporting gel upon sufficient addition of VEGF. 	 sodium citrate buffer (-27,000 deg cm 2 dmol- '). The differ- 
After mixing, the hydrogels were stored at 4° C. The stored 20 ence between the measured ellipticity and the ellipticity of the 
hydrogels were equilibrated to room temperature prior to 	 unfolded monomer is related to concentration and can be fit to 
theological characterization (typically several minutes). 	 determine the Kd of the dimerization, via standard fitting 
bFGF Release and Hydrogel Erosion Experiments 	 procedures well-described in the literature. The calculated 
bFGF release and hydrogel erosion experiments were per- 	 equilibrium constant of unfolding, Kd, is 3.48±0.03 µM. 
formed at 4° C. in 24-well polystyrene assay plates (Corning 25 Solutions of PF4ZIP attached to star-PEG were also studied 
Inc., Corning, N.Y.), blocked with PBS containing 5% BSA 	 via CD, to ensure that conjugation to PEG did not signifi- 
and 0.05% Tween 20 (Sigma, St. Louis, Mo.). The wells were 	 cantly alter the association of the PF 4ZIP coiled-coils. As 
aspirated and washed 4 times with 0.05% Tween 20 in PBS 	 shown in FIG. 17(a), the spectra of PEG-PF 4ZIP are essen- 
before loading samples. Afterward, 200 ltL hydrogel was 	 tially identical to the spectra obtained for the isolated PF 4ZIP. 
placed on the bottom of each well and 2.8 mL PBS was added 30 Slight differences in MRE values likely arise from uncertain- 
carefully over each gel. 1 mL PBS was taken out of the well 	 ties in the precise peptide concentrations for the PEG-PF 4ZIP 
at 1, 2, 6 and 24 h and then each following day, followed by 	 samples. The Kd value derived from the best fit of the con- 
replacement with 1 mL fresh PBS. The amount of bFGF in 	 centration dependence of (FIG. 17(b)) for PEG-PF 4ZIP is 
each sample was measured with a bFGF Quantikine kit (R&D 	 0.93 µM. The PF4ZIP concentrations during NMR character- 
Systems, Minneapolis, Minn.). Thehydrogel erosionkinetics 35 ization and hydrogel formation and characterization are 
were conducted on the same samples used for bFGF release 	 always much greater than these measured Kd values (e.g., 200 
experiments. 	 µM and higher), suggesting that PF 4ZIP will exist as a fully 
Results 	 folded dimer under those conditions. 
Oligomerization of PF 4ZIP 
	
Heparin-binding Affinity 
Our initial studies were aimed at determining the oligomer-  40 Our previous investigations of PEG-LMWH/PEG-HBP 
ization properties of the coiled-coil PF 4ZIP, as such informa- 	 hydrogels suggested that the viscoelastic properties of the 
tion is relevant to the subsequent use of the PF 4ZIP in hydro- 	 noncovalently assembled hydrogels were related to the hep- 
gel formation. No such characterization was necessary for the 	 arin-binding kinetics and affinities of the peptides (from anti- 
other HBPs, as they do not form higher-order assemblies. 	 thrombin III (ATIII) or heparin interacting protein (HIP)). 
Circular dichroic spectroscopy studies were conducted to 45 Heparin-sepharose affinity chromatography and SPR experi- 
assess the folding of the PF 4ZIP under various conditions. 	 ments were therefore used to compare the heparin-binding 
Solutions of PF4ZIP dissolved in PBS were scanned from 250 	 affinity of the various HBPs. Results of these experiments are 
nun to 200 nun at varying temperatures between 5° C. and 75° 	 summarized in Table 2. 
TABLE 2 
Heparin binding affinity data (at 25° C.) for heparin- 
binding peptides determined via affinity chromatography and SPR. 
Salt required for 
elution from heparin 
Peptide column (mM) 	 ka (M-'s 1) 	 kd (s 1) 	 K, (pM) 
ATIII' 	 594±2 	 1.56±0.06x102 2.00±0.3x10-3 	 12.9±1.3 
HIP' 	 687±1 	 1.10±0.08x103 4.64±0.02x10-3 	 4.20±0.3 
PF4, 962 ± 10 	 2.24 ± 0.05 x 10 5 2.56 ± 0.10 x 10-3 	 1.15 ± 0.03 x 10-2 
The errors are derived from the average of duplicate measurements 
'Data from previously reported studies (N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiicic, E. M. Furst, Rheological 
characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels, Biomacromolecules 6 (4) 
(2005) 1931-1940) 
C. The CD spectra of PF 4ZIP at a variety of temperatures 65 	 For heparin affinity chromatography experiments, HBPs 
show an isodichroic point at 203 mu, validating the existence 	 were loaded onto a heparin-sepharose column, and then 
of a two-state equilibrium. At temperatures below 55° C., the 	 eluted with buffer of increasing NaCl concentration. The 
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concentration of NaCl required for peptide elution is used as 
an indication of the affinity of the peptide for heparin. The 
elution of the peptides from the heparin-sepharose column 
required a salt concentration of 962±10 mM for the PF 4ZIP 
peptide. The salt concentration required to elute PF 4ZIP 
(962±10 mM) is higher than that measured for the ATIII 
peptide (594±2 mM) and for the HIP peptide (687±1 mM), 
indicating that PF 4ZIP has higher heparin-binding affinity 
than the ATIII and HIP peptides and should therefore be 
competent for hydrogel assembly. These results are consis-
tent with previous reports indicating that similarly high con-
centrations of NaCl were required to elute 125I-labelled 
PF4ZIP bound to a heparin-sepharose column in 0.02 M 
Tris-HCl buffer pH 7.0 containing 0.05 M NaCl. 
In SPR experiments, the interaction of the peptides with a 
LMWH-modified SA chip surface was determined under 
conditions described in the experimental section. Neither 
nonspecific binding of heparin-binding proteins to SA chips 
nor chip instability was observed in any of the SPR measure-
ments. In addition, no mass transport limitation or linked 
reactions were indicated. The measured association of the 
PF4ZIP with LMWH proceeds with a rate constant of 
2.24±0.05x105 M-1 s- ',  whilethe dissociation proceeds with 
a rate constant of 2.56±0.10x10 -3 s -1 , yielding a KD of 
approximately 1.15±0.03x10-2  µM. These faster association 
kinetics, relative to those reported for the ATIII and HIP 
(Table 2) (see also N. Yamaguchi, B. S. Chae, L. Zhang, K. L. 
Kiick, E. M. Furst, Rheological characterization ofpolysac-
charidepoly (ethylene glycol) star copolymer hydrogels, 
Biomacromolecules 6 (4) (2005) 1931-1940) are the primary 
cause of the lower measured KD values for PF 4ZIP-LMWH 
binding, and the trend of the dissociation constants is consis-
tent with the chromatography results. The more rapid asso-
ciation rate, coupled with the similar dissociation rate, of 
PF4ZIP versus the other HBPs, points to the successful for-
mation of hydrogels between PEG-PF 4ZIP and PEG-
LMWH. The measured KD of the binding between PF 4ZIP 
and LMWH is lower than the measured Kd of dissociation of 
the coiled-coil obtained from CD experiments, which may 
suggest that the LMWH-functionalized surface facilitates 
coiled-coil formation. Nevertheless, the equilibrium con-
stants of dissociation determined via both methods are sub-
stantially lower than the concentrations employed during 
hydrogel formation experiments (see below). 
Temperature Dependence of PF 4ZIP Binding 
The heparin-binding kinetics between LMWH and PF 4ZIP 
were monitored via SPR at several temperatures between 5° 
C. and 37° C., to determine potential changes in binding 
kinetics that might alter hydrogel properties under physi-
ological conditions. Data from these experiments are shown 
in Table 3. 
TABLE 3 
valently assembled hydrogels based on PF 4ZIP and LMWH 
interactions should exhibit consistent mechanical properties 
at these temperatures. 
PEG-LMWH/PEG-HBP Hydrogel Formation 
5 	 Via 1 H NMR spectroscopy, functionalization of the star 
PEG with HBPs was determined to be at least 59%, indicating 
that PEG-HBPs meet the functional requirement (at least one 
binding partner exhibits f>2) for crosslinking a hydrogel 
upon interaction with PEG-LMWH (which showed a func- 
lo tionalization of 81%, as determined via NMR). (see N. 
Yamaguchi, K. L. Kiick, Polysaccharide poly (ethylene gly-
col) star copolymers as scalblds for the production of bioac-
tive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930; 
and N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick, E. M. 
15 Furst, Rheological characterization of polysaccharidepoly 
(ethylene glycol) star copolymer hydrogels, Biomacromol-
ecules 6 (4) (2005) 1931-1940). 
Accordingly, solutions of the two polymer conjugates in 
PBS (2.5 wt % of the PEG-LMWH and 5 wt % of the PEG- 
2o HBP) were mixed at various ligand molar ratios to form 
hydrogels. Ligand molar ratios of 9:0.5 and 7.5:2.5 (LMWH: 
PF4ZIP) were used to yield the PEG-LMWH/PEG-PF4ZIP 
hydrogels. Similar ratios were used for the formation of func-
tionalized crosslinked matrices from mixtures of PEG- 
25 LMWH with either PEG-ATIII or PEG-HIP, and any PEG-
HBP conjugate should be useful in a similar manner. The 
application of such ratios was employed to maximize the 
excess LMWH available for growth factor binding (see 
below). Before addition of PEG-PF 4ZIP, the 2.5 wt % of the 
30 PEG-LMWH was uniform and translucent. In addition, the 
water-like viscosity of the PEG-PF 4ZIP solution indicated 
that there was no significant crosslinking of the peptide-
terminated star polymers via intermolecular coiled-coil for-
mation, although some oligomers of the PEG-PF 4ZIP bio- 
35 conjugates may exist in solution. The formation of self-
supporting, opaque gels was immediately apparent upon 
mixing the two polymer solutions. A schematic of the assem-
bly of the hydrogels is shown in FIG. 18. This assembly is 
operative regardless of the identity of the PEG-HBP. 
4o Bulk Rheology 
The mechanical properties of the PEG-HBP containing 
hydrogels were characterized via theological frequency 
sweep experiments on bulk samples. The frequency sweep 
results for PEG-LMWH/PEG-PF 4ZIP hydrogels (FIG. 19) 
45 show that the storage modulus G'(w) is significantly larger 
than the loss modulus G"(w) over all measured frequencies 
and G'(w) exhibits a pronounced plateau extending to fre-
quencies of tens of reciprocal seconds, indicating a viscoelas-
tic gel. Essentially identical results are obtained regardless of 
50 the identity of the PEG-HBP. The magnitude of G'(w) and 
G"(w) also increases as the molar ratio of the peptide com-
ponent is raised. The average G'(w) increases from an average 
value of 70 Pa for PEG-LMWH to approximately 80 and 180 
Pa for hydrogels with molar ratios of LMWH to PF4ZIP of 
55 9:0.5 and 7.5:2.5, respectively. The average G"(w) also 
increases monotonically with higher molar ratio of the pep-
tide component, from less than 10 Pa for PEG-LMWH to 
more than 30 Pa for hydrogels with molar ratios of LMWH to 
PF4ZIP of 7.5:2.5. Bulk theology experiments were also 
60 performed on the samples at various gap heights of 1 mm, 0.5 
mm, and 0.25 mm. At frequencies from 0.1 to 63 Hz, the 
observed identical dynamic moduli at different gap heights 
indicate that no significant slipping occurs in that frequency 
Heparin-binding affinity data for PF4Z1p at different 
temmratures. as determined via SPR. 
Temper- 
ature 
	
C C.) 
	 (M-is 1) 	 "'(S -1 ) 	 KD (!M) 
	
5 	 1.56±0.01x10 5 3.74±0.17x10-3 	 2.41±0.10x10-8 
	
15 	 1.90 ± 0.04 x 10 5 1.67 ± 0.03 x 10-3 	 8.82 ± 0.02 x 10
-g 
	
25 	 2.24 ± 0.05 x 10 5 2.56 ± 0.10 x 10-3 	 1.15 ± 0.03 x 10-8 
	
37 	 5.11±0.02x105 2.44±0.08x10-3 	 4.78±0.14x10-g 
The errors are derived from the average of duplicate measurements 	 range. 
65 	 The strengthening effects on storage modulus upon addi- 
The measured on and off rates fluctuate only slightly 	 tion of PEG-HBP to PEG-LMWH are presented in FIG. 20 
throughout the temperature range, suggesting that nonco- 	 for G' (w=0.1 Hz) plotted as a function of the ratio of HBP to 
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LMWH in the samples, with moduli normalized by the initial 
storage modulus of PEG-LMWH. The plateau in the modulus 
with increasing PF 4ZIP or HIP concentration may imply that 
the HBP-binding sites on LMWH have been saturated. The 
increase in the elastic modulus upon addition of PEG-PF 4ZIP 
for the PEG-LMWH/PEG-PF 4ZIP hydrogels is lower than 
that observed with addition of PEG-HBP for the PEG-
LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP hydro-
gels. Literature reports suggest that at least 4 tetrasaccharides 
(16 units) are required for efficient heparin-PF4 protein inter-
actions, while HIP- andATIII-binding sites are believed to be 
similar pentasaccharides in heparin. The fewer PF 4-binding 
sites on LMWH could lead to the lower storage modulus 
plateau value and lower slope in FIG. 20 for the PEG-
LMWH/PEG-PF4ZIP hydrogels than that observed for the 
PEG-LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP 
hydrogels. These results indicate two things. First, the 
mechanical properties of the hydrogels are initially estab-
lishedby the self-interaction/assembly of PEG-LMWH. Sec-
ond, the dependence of storage modulus on HBP:LMWH 
ratio clearly indicates that the PEG-HBPs mediate crosslink-
ing of the networks and that the interactions between HBP 
and LMWH modulate the mechanical properties of the matri-
ces. 
A similar dependence of theological properties on the con-
centration of heparin-binding cross-linker was observed for 
PEG-LMWH crosslinked with VEGF. Laser tweezer 
microrheology experiments, in this case, confirmed the elas-
tic behavior of the hydrogels at low and moderate frequen-
cies, and also demonstrated that the development of elastic 
properties of the network are dependent on the concentration 
of VEGF present in the network. Microrheology character-
ization was conducted on 4 wt % hydrogels in order to reduce 
the elastic modulus sufficiently for measurement. 8 wt % 
hydrogels provide improved mechanical properties, although 
a variety of concentrations could be used depending on the 
desired application. 
The theological properties of the PEG-LMWH/PEG-
PF4ZIP hydrogels were also investigated at physiological 
temperature. The mechanical properties of the hydrogels with 
molar ratios of LMWH to PF 4ZIP of 9:0.5 and 7.5:2.5 were 
examined. The frequency sweep data for the hydrogel 
(LMWH:PF4ZIP=9:0.5) are presented in FIG. 21. The 
moduli at 25° C. or 37° C. are essentially identical, with an 
identical frequency dependence, although the gels at 37° C. 
exhibit slightly lower loss moduli at higher frequencies. The 
materials are therefore also elastic hydrogels at 37° C., in 
corroboration of the SPR studies. This lack of temperature 
dependence is also observed in the hydrogel with higher 
PF4ZIP content, reflecting the temperature insensitivity of 
both the PF4-LMWH interactions and the LMWH-LMWH 
interactions. 
Shear recovery data for the PEG-LMWH/PEG-PF 4ZIP 
hydrogels are exhibited in FIG. 22. Both the extent and time-
dependence of recovery were determined in these experi-
ments. FIG. 22 indicates that after the hydrogels are subjected 
to a steady shear rate as high as 1000 s -i , they essentially 
immediately recover their elastic properties, so only a slight 
reduction in modulus can be measured. In addition, the 
moduli at 25° C. and 37° C. are equal, with a matching 
kinetics of recovery. The data are consistent with previous 
theological frequency sweep studies (FIG. 21). The immedi-
ate recovery and stability of the PEG-LMWH/PEG-PF4ZIP 
hydrogels even after subjected to high shear suggests their 
potential utility in injectable applications. 
32 
Growth Factor Release and Hydrogel Erosion 
The release of growth factors from these hydrogels in vitro 
has also been investigated. Although covalently crosslinked, 
heparin-containing hydrogels have been shown to be useful 
5 for release of bFGF, physically crosslinked hydrogels could 
provide an alternative protein-delivery matrix without the 
need for potentially toxic crosslinking reagents. 
The bFGF release and hydrogel erosion experiments were 
performed at 4° C. in 24-well polystyrene assay plates. A 2.5 
io wt % solution of PEG-LMWH with bFGF was prepared via 
dissolving PEG-LMWH and bFGF in PBS at a final molar 
ratio of approximately 1:1,500,000 (bFGF to LMWH). Sec-
ondly, a 5 wt % solution of PEG-PF 4ZIP (or other PEG-HBP) 
in PBS was added to the PEG-LMWH/bFGF at a ligand molar 
15 ratio of 8:1 (LMWH:PF4ZIP dimer). Other molar ratios can 
also be used, depending upon the desired rate of release of the 
growth factor and/or desired rate of erosion of the network. 
Assuming that all HBPs on the PEG-HBP termini bind 
LMWH, the molar ratio of bFGF to available LMWH in the 
20 PEG-LMWH/PEG-HBP hydrogels is approximately 
1:1,300,000. 
Data from studies of bFGF release from PEG-LMWH/ 
PEG-HIP and PEG-LMWH/PEG-PF 4ZIP hydrogels are 
summarized in FIG. 23. As shown in the figure, a burst release 
25 of bFGF ranging from 10 to 25% (depending on gel identity) 
is observed, followed by a slow release of bFGF over 10 days, 
to a maximum measured release ranging from approximately 
20 to 35%. Such release profiles are of potential use in 
neovascularization, wound repair, and tissue engineering 
3o applications. As shown in FIG. 23, the bFGF is released 
slightly more quickly from the PEG-LMWH/PEG-PF 4ZIP 
hydrogels than from the PEG-LMWH/PEG-HIP hydrogels, 
indicating that the rates of release of growth factor from these 
hydrogels are tunable based on hydrogel composition. The 
35 PEG-LMWH/PEG-HIP hydrogel demonstrates higher stor-
age and loss moduli than the PEG-LMWH/PEG-PF 4ZIP 
hydrogels. The observed burst release is similar in value to 
previously reported burst release in other heparinized hydro-
gel system, and the linear release following the initial burst in 
40 those hydrogel systems has been successfully applied to 
stimulate cell proliferation. 
Hydrogel erosion kinetics are also shown in FIG. 23. In the 
case of the PEG-LMWH/PEG-PF 4ZIP hydrogels, PEG-
LMWH-Alexa Fluor 350 was pre-mixed with PEG-LMWH 
45 at a weight ratio of 1:158 to facilitate tracking of the eroded 
PEG-LMWH via fluorimetry. The erosion profile of the PEG-
LMWH/PEG-HIP hydrogels was determined gravimetrically 
in the transwell assay format in conjunction with the bFGF 
release experiments. As shown in the figure, a burst erosion of 
50 10 to 30% is initially observed (depending on hydrogel com-
position), followed by a slow erosion to a maximum of 30 to 
50% (again, depending on hydrogel composition). As is also 
indicated in this figure, the growth factor release is directly 
correlated to the erosion of the hydrogel, and can therefore be 
55 controlled by modulating hydrogel mechanical properties. 
Modulating the affinity of the growth factor to the hydrogel 
will also serve as an additional strategy to control release 
rates. 
Growth factors released from hydrogels of these general 
60 compositions have also been shown to be bioactive, indicat- 
ing the utility of these matrices in desired applications. For 
example, bFGF released from PEG-LMWH functionalized 
hydrogels (covalently crosslinked model systems) (proce- 
dure for covalent crosslinking is provided in N. Yamaguchi, 
65 K. L. Kiick, Polysaccharide poly (ethylene glycol) star 
copolymers as scalolds for the production of bioactive hydro- 
gels, Biomacromolecules 6 (4) (2005) 1921-1930, which is 
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incorporated herein by reference) has been shown, via MTT 	 shown in FIG. 24, and indicates the degree of hydrogel ero- 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- 	 sion. Specifically, FIG. 24(a) shows the release profiles of 
mide) proliferation assays, to increase proliferation of 	 PEG-LMWH from the [PEG-LMWH/VEGF] and [PEG- 
HUVECs (human umbilical vein endothelial cells) in a 	 LMWH] in the presence of PAE/KDR, PAE cells and in the 
bFGF-dose-responsive manner. In these assays, the amount 5 absence of cells. Burst release was observed in all sets of gels, 
of yellow MTT oxidized to purple formazan is measured 	 with 49.0±2.8%release of PEG-LMWH from [PEG-LMWH/ 
spectrophotometrically as a function of the amount of bFGF 
	 VEGF] in the presence of PAE/KDR and an average of 
loaded in the hydrogel. Average increases in formazan salt 
	 43.6±6.8% release in other samples. The cumulative release 
formation ranged from 1.5 to 4 fold in the bFGF proliferation 	 of PEG-LMWH at day 4 under all different experimental 
experiments. In another set of experiments, VEGF released io conditions is shown in FIG. 24(b) to facilitate comparison. 
from the PEG-LMWH/VEGF hydrogels has been shown to 	 The release profiles of PEG-LMWH in all samples were 
increase the rate of proliferation of porcine aortic endothelial 	 similar during this experiment, except for that of [PEG- 
(PAE) cells in DMEM media. Assays were conducted in a 	 LMWH/VEGF] in the presence of PAE/KDR; this exception 
transwell assay format as described in N. Yamaguchi, K. L. 	 was statistically significant from day 3 onward (p<0.001 at 
Kiick, Polysaccharide poly (ethylene glycol) star copolymers 15 day 4 and p<0.007 day 5), with an approximate 20% differ- 
as scafblds for the production of bioactive hydrogels, Biom- 	 ence in release between the samples after day 4. The [PEG- 
acromolecules 6 (4) (2005) 1921-1930. Measured increases 	 LMWH/VEGF] hydrogel was completely eroded by day 4 in 
in the proliferation rate, assessed via cytometry, have ranged 
	
the presence of PAE/KDR, whereas the hydrogels in all other 
from 25-50%. These results complement and are similar to 	 samples remained intact until the end of the release experi- 
the results obtained in Example 3, which indicate the bioac-  20 went (day 5). Comparison of PEG-LMWH release from 
tivity of growth factor-loaded electrospun matrices. Similar 	 [PEG-LMWH/VEGF] versus [PEG-LMWH] hydrogels in 
bioactivity of any growth factor sequestered in these matrices 	 the presence of PAE/KDR indicated the greater rate of ero- 
is expected, based on these results, and on the general obser- 	 sion of the VEGF-crosslinked hydrogel (FIG. 24(b) 
vation of growth factor activity preservation in heparinized 
	 (p<0.001)), confirming that the binding of VEGF to 
matrices. 	 25 VEGFR-2 accelerates the erosion of [PEG-LMWH/VEGF]. 
The fact that the release of PEG-LMWH for all other samples 
Example 5 
	
is essentially identical confirms not only that both VEGF and 
VEGFR-2 are necessary for the accelerated erosion and but 
Cell-Mediated Delivery and Targeted Erosion of VEGF- 	 also that other cell-surface molecules of the PAECs do not 
Cross-Linked Hydrogels 	 3o accelerate erosion of these gels. Otherwise, the release of 
To test the potential of these hydrogels to selectively 	 PEG-LMWH from the gels in the presence of PAE would be 
release VEGF (and thus erode) in response to cells that over- 	 greater than that observed in the absence of cells. In addition, 
express VEGFR-2, two engineered endothelial cell types 	 given the similarity in release profiles of the [PEG-LMWH] 
were employed. [PEG-LMWH/VEGF] was incubated in the 	 gels in the presence and absence of PAE cells, erosion of 
presence of porcine aortic endothelial cells (PAECs) engi-  35 [PEG-LMWH] is suggested to occur via passive diffusion. 
neered to overexpress (2.5x10 5 VEGFR-2 per cell; PAE/ 	 This result clearly indicates that the presence of VEGFR-2 on 
KDR) or in the presence of cells lacking the transcript for 	 cell surfaces accelerates the erosion of [PEG-LMWH/VEGF] 
VEGFR-2 (PAE). The cumulative release of VEGF and PEG- 	 hydrogels. 
LMWH were monitored in a transwell assay cell culture 	 Release of VEGF 
format in which hydrogels were placed in the transwell insert 40 Release of VEGF in response to the VEGFR-2 presenting 
and PAECs were cultured on the PS surface of the well of a 	 cells was also investigated for comparison with PEG-LMWH 
24-well plate. A well lacking any cells was employed as a 	 release. The release of VEGF from [PEG-LMWH/VEGF] 
control. This transwell assay format optimized cell prolifera- 	 hydrogels in the presence and absence of cells was monitored 
tion and was necessary given that the hydrogels lack any 	 by measuring the radioactivity of 125I-labeled VEGF in the 
cell-adhesive domains; this format is also representative of 45 collected medium. The release profiles are shown in FIG. 25. 
situations in which the [PEG-LMWH/VEGF] would be 	 In general, the release profiles of VEGF exhibited very simi- 
employed as a drug delivery vehicle. The two types of PAE 
	
lar trends to those observed for PEG-LMWH release from 
cells were also used to evaluate the impact, on endothelial cell 
	 [PEG-LMWH/VEGF] hydrogels. The VEGF release in the 
proliferation, of the released VEGF from the non-covalently 	 presence of PAE/KDR showed a burst release of 55.6±3.0% 
assembled [PEG-LMWH/VEGF]. The phosphorylation of 5o at day 1, and reached a maximum of 92.9±7.8% at day 4. In 
VEGFR-2 was also investigated in the presence and absence 	 contrast, burst release of 56.7±3.8% was observed at day 1 in 
of the VEGF-containing hydrogel to determine whether the 	 the presence of PAE, and the cumulative release was 
release of the VEGF activated the target receptor. 	 75.7t5.1% at day 5. The initial release of VEGF from [PEG- 
Release of PEG-LMWH 
	
LMWH/VEGF] hydrogels in the absence of cells was 
The impact of VEGFR-2, the main mitogenic VEGF recep-  55 43.4±3.4% with a cumulative release of 79.6±2.0% at day 5. 
tor, on hydrogel erosion was investigated by monitoring the 	 VEGF release from [PEG-LMWH/VEGF] reached the maxi- 
release of the PEG-LMWH carrier from the gels in the pres- 	 mum at day 4 in the presence of PAE/KDR, concurrent with 
ence of PAE cells equipped with or without the VEGFR-2, i.e. 	 the complete erosion of the gel. 
PAE/KDR or PAE, respectively. PAE/KDR or PAE were 	 That the release of VEGF from the [PEG-LMWH/VEGF] 
seeded in 24-well plates for each data point (1, 2, 3, 4, and 5 60 was in fact mediated by VEGFR-2, rather than by other select 
days; data were not collected after day 5 owing to the conflu- 	 surface molecules present on PAE/KDR, was also confirmed 
ence of the PAECs.). The [PEG-LMWH/VEGF] or [PEG- 	 by the correlation of the amount of liberated VEGF with the 
LMWH] hydrogels were placed on a transwell support and 	 concentration of the VEGFR-2 present in the PAE/KDR cul- 
these were inserted in each of the cell-containing wells, 	 tures, as determined by immunochemical methods. The con- 
respectively. The amount of PEG-LMWH in the removed 65 centration of VEGFR-2 from the PAE/KDR cells in the pres- 
aliquots of medium was evaluated via toluidine blue assay. 	 ence of the [PEG-LMWH/VEGF] was measured daily using 
The cumulative release of PEG-LMWH from hydrogels is 	 an ELISA kit for total VEGFR-2. The cumulative release of 
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VEGF is graphically presented versus the measured concen- 	 rately in the presence of 100 ng•mL -i (2.63 nM) soluble 
tration of VEGFR-2 in FIG. 26. The data presented in FIG. 26 	 VEGF as the control. The number of cells was quantified at 
clearly indicate the correlation of the release of VEGF from 	 day 4 owing both to the complete erosion of the [PEG- 
[PEG-LMWH/VEGF] with the total amount of VEGFR-2 	 LMWH/VEGF] at day 4 and the confluence of the PAE/KDR 
present on PAE/KDR, indicating that the VEGF release and 5 cells after day 5. As shown in the data, the PAE/KDR cultures 
consequent [PEG-LMWH/VEGF] erosion was accelerated 	 in the presence of [PEG-LMWH/VEGF] show cell numbers 
due to the demand for VEGF by VEGFR-2. These results 	 approximately 120% of that observed for the control (PAE/ 
suggest that non-covalently assembled [PEG-LMWH] 	 KDR in the presence of soluble VEGF; p<0.003). Impor- 
hydrogels provide a viable strategy for targeted hydrogel 	 tantly, the number of PAE/KDR cells was Ca. 30% higher in 
erosion and drug delivery for any therapeutic compound 10 the presence of [PEG-LMWH/VEGF] than in the presence of 
capable of non-covalent binding to heparin, for example, 	 [PEG-LMWH] (p<0.001). This result is completely consis- 
growth factors and growth factor agonists and antagonists. 	 tent both with the increased phosphorylation of VEGFR-2 as 
Phosphorylation of VEGFR-2 	 a result of VEGF release from [PEG-LMWH/VEGF]. In 
The effect of released VEGF, from the [PEG-LMWH/ 	 addition, the effect of [PEG-LMWH/VEGF] hydrogels onthe 
VEGF] hydrogel, on the activation of VEGFR-2 was moni-  15 proliferation of PAE, which lacks the VEGFR-2 transcript, 
tored via assessment of the degree of tyrosine phosphoryla- 	 was no different than the effect of the [PEG-LWMH], indi- 
tion of VEGFR-2 observed in response to released VEGF. 	 cating the key role of the VEGF/VEGFR-2 interactions on the 
Upon binding with VEGF, the VEGFR-2 undergoes dimer- 	 observed cell proliferation. These results indicate that VEGF 
ization and tyrosine phosphorylation, resulting in mitogenic, 	 released from the hydrogel is functional and selectively 
chemotactic, and prosurvival signals. The efficacy of deliv-  20 increases proliferation of VEGFR-2-expressing endothelial 
ered VEGF, and the responsiveness of the endothelial cells to 	 cells. 
the gels, can therefore be indicated by the level of VEGFR-2 
phosphorylation, which was determined immunochemically. 	 Example 6 
FIG. 27 presents the fraction of phosphorylated VEGFR-2 
(relative to the total VEGFR-2 isolated from PAE/KDR cells), 25 	 In some embodiments, erodible hydrogels are prepared via 
as a function of time. The cells were lysed at each data point 	 the interactions of a soluble PEG-LMWH with heparin-bind- 
in the presence of kinase inhibitors to maintain the level of 
	
ing growth factors or heparin-binding peptides. In other 
phosphorylation at the time of cell collection. The concentra- 	 embodiments, erodible hydrogels are prepared by the incor- 
tion of total VEGFR-2 and concentration of phosphorylated 	 poration of both covalent and noncovalent crosslinking strat- 
VEGFR-2 in lysates were measured using ELISA kits. As 30 egies. Hydrogels synthesized via such strategies are compe- 
shown in the data, the phosphorylated fraction of VEGFR-2 	 tent for formulation into bulk and nanoparticulate materials 
in PAE/KDR cultures incubated with the VEGF-releasing 	 with application in tissue engineering and cell-targeted deliv- 
hydrogel [PEG-LMWH/VEGF] increased from 0.57±0.05 at 	 ery FIG. 29 shows a number of embodiments involving 
day 1 to 0.79±0.09 (p<0.003) at day 4. This level was signifi- 	 covalently crosslinked PEG-LMWH conjugates that are fur- 
cantly higher than that observed in control experiments in 35 ther noncovalently crosslinked via interactions between 
which PAE/KDR were cultured in the presence of the [PEG- 	 PEG-HBP, lysozyme or VEGF and the heparinized network. 
LMWH] hydrogel (0.28±0.07, FIG. 27(a)), as well as that of 	 In one embodiment, the present invention is directed to a 
a control in which cultures of PAE/KDR were incubated 
	
hydrogel comprising a polymer matrix comprising a nonco- 
without hydrogel (0.22±0.04, not shown); in addition, the 	 valent crosslink and a covalent crosslink, wherein the nonco- 
level of phosphorylation in the control did not show a clear 40 valent crosslink comprises a first and a second PEG-LMWH 
increase with time. 	 conjugate and a heparin-binding compound, wherein the 
The fraction of phosphorylated VEGFR-2 was plotted 
	
PEG molecule of each conjugate is covalently attached to the 
against the cumulative release of VEGF from the [PEG- 	 polymer matrix, and wherein the LMWH molecule of each 
LMWH/VEGF] hydrogels, to confirm that phosphorylation 	 conjugate is covalently attached to the PEG molecule of the 
of the receptor was correlated with VEGF release. As shown 45 same conjugate and noncovalently attached to the heparin- 
in FIG. 27(b), the fraction of VEGFR-2 phosphorylated was 	 binding compound, and wherein the covalent crosslink com- 
linearly correlated to the cumulative release of VEGF, con- 	 prises a first and a second PEG molecule and a LMWH 
firming that the released VEGF is interacting with and stimu- 	 molecule, wherein each PEG molecule is covalently attached 
lating the phosphorylation of VEGFR-2, and corroborating 	 to the polymer matrix and covalently attached to the LMWH 
this interaction as the relevant one in modulating hydrogel 50 molecule. 
behavior (release and erosion). It is also of note that although 	 In another embodiment, the present invention is directed to 
the phosphorylation of VEGFR-2 increased with released 	 a hydrogel comprising a polymer matrix comprising a non- 
VEGF, the total VEGFR-2 expression level per cell did not 	 covalent crosslink and a covalent crosslink, wherein the non- 
change ((8.7±1.2)x1 0-s ng•mL-i per cell at day 1 vs. 	 covalent crosslink comprises a first and a second PEG- 
(8.5±0.7)x 10-s at day 4). This suggests that while the [PEG-  55 LMWH conjugate and a first heparin-binding compound, 
LMWH/VEGF] hydrogels are responsive to VEGFR-2 and 	 wherein the PEG molecule of each conjugate is covalently 
induce greater signaling by the cell, they do not alter 	 attached to the polymer matrix, and wherein the LMWH 
VEGFR-2 expression that could present a potentially patho- 	 molecule of each conjugate is covalently attached to the PEG 
logical response. 	 molecule of the same conjugate and noncovalently attached 
Proliferation of PAE Cells 	 60 to the first heparin-binding compound, and wherein the cova- 
The mitogenic effects of VEGF released from the hydro- 	 lent crosslink comprises either (i) a third and a fourth PEG- 
gels, suggested by the phosphorylation data, were corrobo- 	 LMWH conjugate and a second heparin-binding compound, 
rated in cell culture. FIG. 28 presents the percentage of cell 	 wherein the PEG molecule of each conjugate is covalently 
growth (at day 4, relative to a control) of PAE/KDR and PAE 	 attached to the polymer matrix, wherein the LMWH molecule 
in the presence of [PEG-LMWH/VEGF] and [PEG-LMWH], 65 of each conjugate is covalently attached to the PEG molecule 
as colorimetrically monitored via CELLTITER-BLUE® 	 of the same conjugate, and wherein the LMWH molecule of 
((Promega) reagent assay. Each cell type was cultured sepa- 	 each conjugate is either covalently attached to the second 
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heparin-binding compound or wherein the LMWH molecule 
of the third conjugate is covalently attached and the LMWH 
molecule of the fourth conjugate is noncovalently attached to 
the second heparin-binding compound, or (ii) a first and a 
second PEG molecule and a third heparin-binding com-
pound, wherein each PEG molecule is covalently attached to 
the polymer matrix and covalently attached to the third hep-
arin-binding compound. 
The embodiments comprising both covalently bound and 
noncovalently bound heparin-binding compounds are useful 
for releasing these heparin-binding compounds at different 
times and a different rates. The noncovalently bound heparin-
binding compounds may be released as provided for in 
Example 5 and elsewhere in the specification. For example, 
the noncovalently bound heparin-binding compounds may be 
released in burst, or relatively short time as compared to the 
covalently bound heparin-binding compounds. The 
covalently bound heparin-binding compounds may be 
released at a slower rate by conventional means. At least one 
application of the differential rate of release of the heparin-
binding compounds is for stent or blood vessel construction. 
For the embodiments above, the PEG and the PEG mol-
ecules in each conjugate can be the same or different types of 
PEG. In one embodiment, the PEG-LMWH conjugates in the 
noncovalent crosslinkings comprise multi-arm PEG, eg. 
4-arm or 8-arm star PEG. Likewise, the first LMWH and the 
LMWH molecules in each conjugate can be the same or 
different types of LMWH. In one embodiment, the LMWH 
molecules comprise nadroparin, dalteparin, reviparin, arde-
parin, enoxaparin, tinzaparin, fondaparinux, parnaparin or 
certaparin. The first and second heparin-binding compounds 
can be the same or different types of compounds. In one 
embodiment, the heparin-binding compounds comprise 
growth factor, cytokine, peptide, peptide-modified polymer, 
protein, polysaccharide, polysaccharide-modified polymer, 
peptoid, peptoid-modified polymer or a small molecular 
drug. In another embodiment, the heparin-binding com-
pounds comprise vascular endothelial growth factor, basic 
fibroblast growth factor, acidic fibroblast growth factor, hep-
arin-binding epidermal growth factor, transforming growth 
factor-beta or nerve growth factor. In another embodiment, 
the heparin-binding compounds comprise a compound 
selected from the group consisting of F56, VI, GU40C4, 
K237 and QK. 
Covalently crosslinked PEG and heparin hydrogel net-
works have been previously investigated using high molecu-
lar weight heparin to yield growth factor delivery depots in 
vivo and in vitro.' °2 The use of a combination of covalent and 
noncovalent crosslinks, however, permit the formulation of 
mechanically robust, yet environmentally responsive, hydro-
gels, sensitive to addition of proteins or other engineered 
macromolecules. In some embodiments, the covalently 
crosslinked portion polymer of the polymer matrix s at least 
1.5, at least 2.0, or at least 3.0 weight percent. In other 
embodiments, the polymer matrix is about 1.5 to about 3.0 
weight percent covalently crosslinked. 
In some embodiments, crosslinking strategies have been 
developed employing LMWH as the heparin species in the 
PEG-based hydrogels. In one particular embodiment, 
LMWH was modified with maleimide groups via the attach-
ment of aminoethylmaleimide (AEM) via simple carbodiim-
ide chemistries to yield a functionality of 1.7 maleimides per 
LMWH chain.' See FIG. 30. 
In some embodiments, linear PEG may be used. In other 
embodiments, multi-arm PEG, e.g. four-arm PEG, four-arm 
star PEG, eight-arm PEG, eight-arm star PEG, may be used. 
Four-arm PEG provides multiple, intermolecular crosslink- 
38 
ing sites. The PEG may be esterified with 3-mercaptoisobu-
tyric acid to provide a neighboring methyl group to the ester 
to stabilize the esterified species and thus increase the degra-
dation timescales. See FIG. 31. 
5 	 These chemical strategies provide a useful and simple 
means to produce LMWH-functionalized hydrogels of vary-
ing mechanical strength, into which additional proteins can 
be added, to provide additional noncovalent crosslinks that 
alter the mechanical properties of the gel and that are envi-
ronmentally responsive. In one particular embodiment, the 
proteins chosen for noncovalent crosslinking may comprise 
lysozyme and VEGF. Lysozyme is a model protein that is 
used to determine the feasibility of preparing and character-
izing a hydrogel crosslinked via both covalent and noncova- 
is lent interactions. Lysozyme is a 14 kDa protein with a pI of 
—10.5, with a positive charge distributed over the surface of 
the protein. 3 Low molecular weight heparin is capable of 
binding 2-3 lysozymes per chain .3  To avoid flocculation of 
lysozyme-heparin complexes prior to gel formation, hydro- 
20 gels may be first formed with subsequent swelling with 
lysozyme solutions. The change in elastic modulus of these 
materials upon the addition of lysozyme is illustrated in FIG. 
32. As shown in FIG. 32, after 100 minutes of equilibration in 
buffer, the hydrogel had reached equilibrium at which it was 
25 then incubated with a lysozyme solution. An immediate 
increase in modulus was observed. FIG. 32 shows a time 
sweep torsion test which shows the increase in loss modulus 
(G", •) and storage modulus (G', O) upon swelling a 2 wt % 
hydrogel with 5 µL 88 mg/ml lysozyme solution at 100 min- 
so utes (LMWH:Lysozyme=3:1), indicatedby the starred arrow. 
In one embodiment, heparin-binding growth factor, 
namely VEGF (vascular endothelial growth factor), is used to 
noncovalently crosslink four arm PEG-low molecular weight 
heparin macromolecules.' The shear modulus of these solely 
ss noncovalently crosslinked materials was approximately 1 Pa. 
The utility and mechanical properties of these solely nonco-
valently crosslinked materials can be improved by the addi-
tion of covalent crosslinking. In some embodiments, hydro- 
40 
gels comprising covalent and noncovalent crosslinking have 
an elastic modulus of at least 5 Pa or at least 10 Pa. In other 
embodiments, hydrogels comprising covalent and noncova-
lent cro s slinking have a elastic modulas of about 5 Pa to about 
10 Pa. 
In FIG. 33, the feasibility to alter the mechanical properties 
45 
of a covalently crosslinked PEG-LMWH gel via the addition 
of VEGF at low concentrations is demonstrated. FIG. 33 
shows a frequency sweep torsion test showing an increase in 
higher frequency mechanical properties for swelling a 3 wt % 
hydrogel with 200 ul 5 mg/ml VEGF solution (Hep: 
so VEGF=33:1). Circles indicate results from swelling with 
buffer, squares from VEGF. Closed symbols are storage 
modulus (G'), open are loss modulus (G"). The data in FIG. 33 
show that a 3 wt % gel swelled with 200 ul of 5 mg/ml VEGF 
shows an increase in torsional stiffness (i.e. shear storage 
55 modulus) with increasing frequency. G" increased by 13x and 
G' increased by 1.7x at 100 rad/s. The responsiveness of the 
hydrogel is apparent at higher frequencies. Lower molecular 
weight heparin should form a more responsive hydrogel than 
higher molecular weight heparin. 
6o In one embodiment, the use of low molecular weight hep-
arins (e.g. Approx Mw 4,500 g/mol, —15 saccharides) is pre-
ferred because the VEGF can engage one LMWH at each of 
the VEGF's heparin-binding sites to yield a functional 
65 crosslink. In some embodiments, the LMWH has a MW less 
than about 6,000 g/mol. In other embodiments, the LMWH 
has a MW of about 3,000 g/mol. The use of PEG-HMWH gels 
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(high molecular weight heparin) displays less VEGF respon-
siveness. VEGF carries two heparin binding domains; each 
domain has been determined to bind 6-8 saccharides; thus, in 
the presence of high molecular weight heparin, it is possible 
for VEGF to bind to a single heparin chain. Such binding 
does not yield a functional crosslink between PEG chains. In 
contrast, the use of LMWH in the network limits this intramo-
lecular binding of VEGF with heparin, and the VEGF binds 
intermolecularly with two separate LMWH and thus links 
two separate PEG chains. 
The feasibility of using this system to create responsive 
hydrogels has been shown. Responsive networks are also 
possible via interactions of covalently crosslinked PEG-
LMWH with a variety of other heparin-binding molecules. 
The use of anti-angiogenic, heparin-binding peptides would 
yield therapeutic materials capable of targeted delivery to 
sites of pathological angiogenesis (e.g., tumors). The follow-
ing Table lists peptides or peptoids that have been shown to 
bind to the VEGFR-2 receptor (also known as KDR), thus 
blocking angiogenesis. These compounds can be attached to 
a heparin binding peptide sequence, SHIP (CKAAKRP-
KAAKDKQTK) (SEQ ID NO: 8) or others, and subsequently 
to 4-arm star PEG to yield heparin-binding, therapeutic 
crosslinking molecules. 
VEGF 
Peptide Sequence SEQ ID NO: Receptor 
F56 $ WHSDMEWWYLLG 4 FLT-1 
V1 9 ATWLPPR 5 KDR 
GU40C4 10 Peptoid — KDR 
K237 11 HTMYYHHYQHHL 6 KDR 
QK12 KLTWQELYQLKYKGI 7 KDR 
In some embodiments, the hydrogels of the present inven-
tion may further comprise a second noncovalent crosslink, 
wherein the second noncovalent crosslink comprises a fifth 
and sixth PEG-LMWH conjugate, and a PEG-heparin-bind-
ing peptide conjugate wherein the PEG-heparin-binding pep-
tide conjugate comprises two heparin-binding peptides that 
are covalently attached to the PEG molecule of the PEG-
heparin-binding peptide conjugate, wherein the PEG mol-
ecule of each PEG-LMWH conjugate is covalently attached 
to the polymer matrix, wherein the LMWH molecule of each 
PEG-LMWH conjugate is covalently attached to the PEG 
molecule of the same conjugate, and wherein the LMWH 
molecule of each PEG-LMWH conjugate is noncovalently 
attached to a different heparin-binding peptide of the PEG-
heparin-binding peptide conjugate. In another embodiment, 
the heparin-binding peptide can be PF 4ZIP, RRP (CGGR-
RRRRRRGG) (SEQ ID NO:9), HIP, SHIP (CKAAKRP-
KAAKDKQTK) or ATIII. As before, the PEG and LMWH 
molecules may be the same as used in the hydrogel or may be 
different compounds. 
FIGS. 34 and 35 show different crosslinks of the present 
invention. The present invention may comprise one or more 
40 
the crosslinks shown in the Figures. Specifically, FIG. 34 
shows different crosslink embodiments of the present inven-
tion. An example of a covalent crosslink comprising PEG and 
LMWH is shown in A. An example of either covalent, non- 
5 covalent or a crosslink with a mixture of both covalent and 
non-covalent attachments is shown in B. The crosslinks in B 
comprise PEG, LMWH and a heparin-binding compound 
(HBC). An example of a noncovalent crosslink comprising 
PEG, LMWH and heparin-binding peptide is shown in C. In 
10 these embodiments, as well as the others disclosed herein, any 
branched (e.g. 4-arm star PEG, 8-arm star PEG) or non-
branched PEG can be used. 
FIG. 35 shows additional example of crosslinked embodi- 
15 ments of the present invention. An example of a covalent 
crosslink comprising PEG and LMWH is shown in D wherein 
a heparin-binding compound is attached to the PEG. Another 
example of a covalent crosslink comprising PEG and a hep-
arin-binding compound wherein a LMWH is attached to the 
20 PEG. 
Experimental 
LMWH-AEM synthesis Low-molecular weight heparin 
(LMWH, Mw 4,500 g/mol) was reacted with N-(2-aminoet-
hyl) maleimide trifluoroacetate salt (AEM, 5 meq.) using 
25 standard procedures to generate LMWH-AEM. The degree of 
maleimide functionalization of approximately 1.7 per 
LMWH chain. 
Four-Arm Poly(ethylene glycol) mercaptoisobutanoate 
30 
(4-arm PEG MIB) synthesis Four-arm hydroxyl terminated 
poly(ethylene glycol) (PEG, Mn 10,000 g/mol) was reacted 
with mercaptoisobutyric acid (MIB) using standard proce-
dures to generate 4arm PEG MIB. 
Hydrogel Formation LMWH AEM and 4arm PEG MIB 
35 were combined to successfully form a hydrogel. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 9 
<210> SEQ ID NO 1 
<211> LENGTH: 34 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 1 
Cys Gly Gly Arg Met Lys Gin Leu Glu Asp Lys Val Lys Lys Leu Leu 
1 	 5 	 10 	 15 
Lys Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Leu 
20 	 25 	 30 
Val Gly 
<210> SEQ ID NO 2 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<220> FEATURE: 
<221> NAME/KEY: MISC_FEATURE 
<222> LOCATION: (3)..(3) 
<223> OTHER INFORMATION: Ala is beta-alanine 
<400> SEQUENCE: 2 
Cys Lys Ala Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Lys Ala 
1 	 5 	 10 	 15 
<210> SEQ ID NO 3 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 3 
Cys Arg Pro Lys Ala Lys Ala Lys Ala Lys Ala Lys Asp Gin Thr Lys 
1 	 5 	 10 	 15 
<210> SEQ ID NO 4 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 4 
Trp His Ser Asp Met Glu Trp Trp Tyr Leu Leu Gly 
1 	 5 	 10 
<210> SEQ ID NO 5 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 5 
Ala Thr Trp Leu Pro Pro Arg 
1 	 5 
<210> SEQ ID NO 6 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
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-continued 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 6 
His Thr Met Tyr Tyr His His Tyr Gin His His Leu 
1 	 5 	 10 
<210> SEQ ID NO 7 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 7 
Lys Leu Thr Trp Gin Glu Leu Tyr Gin Leu Lys Tyr Lys Gly Ile 
1 	 5 	 10 	 15 
<210> SEQ ID NO 8 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 8 
Cys Lys Ala Ala Lys Arg Pro Lys Ala Ala Lys Asp Lys Gin Thr Lys 
1 	 5 	 10 	 15 
<210> SEQ ID NO 9 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 9 
Cys Gly Gly Arg Arg Arg Arg Arg Arg Arg Gly Gly 
1 	 5 	 10 
40 
What is claimed: 4. The hydrogel of claim 2, wherein the cross-linking struc- 
1. A hydrogel comprising a matrix, the matrix comprising tures are (A) and (C). 
a cross-linking structure selected from the group consisting of 5. The hydrogel of claim 1, wherein the cross-linking struc- 
(A) PEG-LMWH-PEG, 
45 tore is (D).  (B) PEG-LMWH-HBC-LMWH-PEG, 
(C) PEG-LMWH-HBC-PEG*-HBC-LMWH-PEG, 6. The hydrogel of claim 1 wherein the portion of the 
(D) PEG-LMWH-PEG-HBC, and matrix covalently crosslinked to the polymer is at least 1.5 
(E) LMWH-PEG-HBC-PEG*; weight percent. 
wherein the hydrogel further comprises a natural or synthetic 50 	 7. The hydrogel of claim 1 having an elastic modulus of at 
polymer; wherein the PEG in a PEG-LMWH conjugate or in least 5 Pa. 
a LMWH-PEG conjugate is covalently bound to the LMWH, 8. The hydrogel of claim 1 wherein the LMWH molecules 
and is covalently bound to the polymer, and is branched or are selected from the group consisting of nadroparin, dalte- 
unbranched; wherein the HBC is bound to the LMWH mol- 55 parm, reviparin, ardeparin, enoxaparin, tinzaparin, fonda- 
ecule by a covalent bond or a non-covalent bond, or wherein parinux, parnaparin or certaparin. 
the HBC is covalently bound to the PEG molecule in the 9. The hydrogel of claim 1 wherein the heparin-binding PEG-LMWH conjugate, or wherein the HBC is covalently 
compound (HBC) is selected from one or more of growth bound to a PEG* molecule, wherein the PEG* molecule is a 
PEG molecule that is not covalently attached to the LMWH, 60 factors, cytokines, peptides, peptide-modified polymers, pro- 
and wherein the PEG* molecule is branched or unbranched. teins, polysaccharides, polysaccharide-modified polymers, 
2. The hydrogel of claim 1, wherein the matrix comprises peptoids, peptoid-modified polymers and small molecule 
two or more cross-linking structures selected from (A), (B), drugs. 
(C), (D), and (E). 65 	 10. The hydrogel of claim 9 wherein the heparin-binding 
3. The hydrogel of claim 2, whereinthe cross-linking struc- compound (HBC) is a growth factor selected from vascular 
tures are (A) and (B). endothelial growth factor, basic fibroblast growth factor, 
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acidic fibroblast growth factor, heparin-binding epidermal 	 12. The hydrogel of claim 1 wherein the heparin-binding 
growth factor, transforming growth factor-beta and nerve 	 compound (HBC) is selected from PF 4ZIP, RRP, HIP, SHIP 
growth factor. 	 and ATIII. 
11. The hydrogel of claim 1 wherein the heparin-binding 
compound (HBC) is selected from the group consisting of 5 
F56, VI, GU40C4, K237 and QK. 
